Psychological treatment for symptoms of posttraumatic stress disorder in vulnerable populations by Yaqubi, Awesta
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2019
Psychological treatment for
symptoms of posttraumatic stress
disorder in vulnerable populations
https://hdl.handle.net/2144/38739
Boston University
   
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
PSYCHOLOGICAL TREATMENT FOR SYMPTOMS OF POSTTRAUMATIC 
STRESS DISORDER IN VULNERABLE POPULATIONS 
 
 
 
by 
 
 
 
 
AWESTA YAQUBI 
 
B.S., Tufts University, 2014 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2019  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2019 by 
 AWESTA YAQUBI 
 All rights reserved  
   
Approved by 
 
 
 
 
First Reader   
 Jean L. Spencer, Ph.D. 
 Instructor of Biochemistry 
 
 
 
Second Reader   
 Travis P. Baggett, M.D., M.P.H. 
 Assistant Professor of Medicine 
 Massachusetts General Hospital 
 
 
 
 
  iv
PSYCHOLOGICAL TREATMENT FOR SYMPTOMS OF POSTTRAUMATIC 
STRESS DISORDER IN VULNERABLE POPULATIONS 
AWESTA YAQUBI 
ABSTRACT 
The lifetime prevalence of posttraumatic stress disorder (PTSD) ranges from 1 to 
14 percent in the general population. Diagnosis is based on criteria that address hallmark 
symptoms of the disorder from re-experiencing the trauma to hyperarousal, emotional 
numbing, and avoidance of memories, thoughts, or feelings associated with the event. 
PTSD is particularly prevalent in vulnerable populations and comorbid with substance 
use disorders, serious mental illness, or both. Psychological treatment options are more 
strongly recommended than pharmacological treatment by the American Psychological 
Association (APA); however, the efficacy of psychotherapy is less studied in vulnerable 
populations for fear that substance use or mental health outcomes will worsen. Prolonged 
exposure (PE) therapy and cognitive processing therapy (CPT) are the most investigated 
forms of cognitive behavioral therapy (CBT) in vulnerable populations and involve 
overcoming the trauma through repeated exposure for PE or processing with a clinician 
for CPT.  
A review of all randomized controlled trials (RCTs) that have evaluated the effect 
of either form of CBT on non-combat PTSD, substance use disorder (SUD), and mental 
health outcomes found that PE administered alongside SUD treatment had the greatest 
positive impact on PTSD and SUD outcomes. PE also had a better impact than CPT on 
PTSD outcomes in individuals with PTSD and serious mental illness (SMI); however, 
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neither form of CBT performed substantially better than the other with respect to mental 
health outcomes.  
In future studies, the impact of psychological treatments on PTSD and other 
health outcomes needs to be assessed on the same variables in larger populations of 
vulnerable individuals that are inclusive and representative of those receiving care for 
SUD and SMI in community health care settings. 
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INTRODUCTION 
 
   Posttraumatic stress disorder (PTSD) affects approximately 6.8 percent of 
individuals in the United States, with 3.6 percent of men and 9.7 percent of women 
having this condition (Fadem, 2012; Friedman, 2015b; Johnson, Krystal, & Southwick, 
2019; Kessler et al., 2005). Trauma type affects the prevalence of PTSD in a population 
(Friedman, 2015b; Johnson et al., 2019). Rates of PTSD in individuals who have 
experienced military combat range from 13 to 20 percent, and non-combat related PTSD 
rates range from 46 to 65 percent among survivors of rape (Johnson et al., 2019).  
 
Etiology of PTSD  
The cause of PTSD is still unclear; however, research has elucidated many factors 
related to it (Daskalakis, McGill, Lehrner, & Yehuda, 2016; Johnson et al., 2019). One of 
the most significant factors associated with the development of PTSD is alteration of the 
human stress response (Daskalakis et al., 2016; Johnson et al., 2019). When a stimulus is 
normally perceived as threatening, the basolateral nucleus of the amygdala is activated 
(Daskalakis et al., 2016; Friedman, 2015e; Johnson et al., 2019). Neurons from the 
basolateral nucleus then activate the central nucleus of the amygdala, which produces 
many of the features of the human stress response, such as fast breathing, sweating, and a 
racing pulse (Friedman, 2015e). Neurons in the central nucleus of the amygdala project 
onto the brainstem, specifically onto areas that activate the release of neurotransmitters, 
such as dopamine, norepinephrine (NE), and serotonin (Friedman, 2015e). When one 
encounters a fearful situation, there is a large release of NE in the brain, which is the 
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microscopic cause of the macroscopic physiological changes associated with the human 
stress response (Friedman, 2015e). 
Although the prefrontal cortex (PFC) is a major regulator of emotional responses 
to stress through its control of the amygdala, in the case of PTSD high levels of NE can 
remove some of the ability of the PFC to control the amygdala (Daskalakis et al., 2016; 
Friedman, 2015e). Also, high levels of NE strengthen the association between the 
traumatic stimulus and the stress response such that repeat exposure or perceived 
exposure to the stimulus produces a heightened stress response (Daskalakis et al., 2016; 
Friedman, 2015e). Whereas a strong threatening stimulus-stress response is 
evolutionarily useful for protecting humans from dangerous stimuli, it is not healthy for 
ultimately innocuous stimuli to produce the same, if not greater, stress responses as 
threatening stimuli (Friedman, 2015e). 
A stressful stimulus also promotes the release of glucocorticoids, mainly cortisol, 
into the bloodstream (Daskalakis et al., 2016). As depicted in Figure 1, stress stimulates 
the hypothalamus to release corticotropin releasing hormone (CRH) (Daskalakis et al., 
2016; Friedman, 2015e). CRH stimulates the anterior pituitary to synthesize and release 
adrenocorticotropic hormone (ACTH), and ACTH acts on the adrenal cortex to stimulate 
glucocorticoid synthesis (Daskalakis et al., 2016). Cortisol, in turn, has a negative 
feedback effect on the hypothalamus and the anterior pituitary, inhibiting the synthesis 
and release of CRH and ACTH, respectively (Friedman, 2015e). However, PTSD is 
associated with the usual negative feedback effect that glucocorticoids have on the 
release of CRH and ACTH being attenuated such that cortisol can no longer negatively 
 3 
regulate these hormones to reduce their concentrations following a stressful stimulus 
(Daskalakis et al., 2016; Friedman, 2015e). Cortisol levels rise, and this increase can lead 
to high blood sugar levels, muscle weakness, and a compromised immune system 
(Daskalakis et al., 2016). 
 
 
Figure 1. Role of the hypothalamic-pituitary-adrenal (HPA) axis in the human stress 
response. This diagram shows the effect of a stressful stimulus that prompts release of CRH from 
the hypothalamus, ACTH from the anterior pituitary, and cortisol from the adrenal glands atop 
the kidneys. Cortisol normally inhibits the production of CRH and ACTH, and it promotes 
various metabolic effects, such as a rise in blood sugar and breakdown of protein in muscle. CRH 
= corticotropin releasing hormone; ACTH = adrenocorticotropic hormone. Taken from (Chivers-
Wilson, 2006). 
 
Thus, the exact cause of PTSD is unclear, as it could be caused by any number of 
mutations (genetic, environmental, or otherwise) that affect components of the human 
stress response from the synthesis and release of neurotransmitters (e.g., NE), 
glucocorticoids (e.g., cortisol), and hormones (e.g., CRH, ACTH) to the receptors for 
these compounds themselves (Johnson et al., 2019). 
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Signs and Symptoms 
   PTSD may develop following one or more traumatic events and is marked by 
trauma-related symptoms that persist for at least one month (American Psychiatric 
Association, 2013; Fadem, 2012; Friedman, 2015e). A clinician can make a diagnosis of 
PTSD based on criteria present in the current Diagnostic and Statistical Manual of Mental 
Disorders (5th edition) (DSM-5) (Fadem, 2012).  
   Criterion A is the traumatic stress criterion and accounts for the various ways that 
an individual may be exposed to trauma (Fadem, 2012; Friedman, 2015a; Friedman, 
Keane, & Resick, 2014; Johnson et al., 2019). Criterion B addresses the “intrusion” 
symptoms of PTSD, or the unwanted, persistent thoughts, feelings, and images related to 
the traumatic event (Fadem, 2012; Friedman et al., 2014; Johnson et al., 2019). Similarly, 
Criterion C attempts to identify the presence of avoidance symptoms, or thoughts and 
actions that individuals may have or carry out, respectively, to cope with the fear caused 
by the intrusion symptoms (Fadem, 2012; Friedman et al., 2014; Johnson et al., 2019). 
Figure 2 summarizes and provides examples of the features of PTSD addressed with each 
criterion in the DSM-5. 
   There exist many surveys and questionnaires that clinicians may use to assess 
patients’ PTSD, or that patients may use to self-report their symptoms (Johnson et al., 
2019). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a 30-item, 
commonly administered tool that assesses all of the variables addressed in the DSM-5 
diagnostic criteria for PTSD in addition to overall symptom severity (Johnson et al., 
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2019; McDonald, Gentes, & Calhoun, 2016). Similarly, the PTSD Checklist for DSM-5 
(PCL-5) is a popular 20-item, self-reported assessment of PTSD symptom severity 
(Johnson et al., 2019; McDonald et al., 2016). 
 
Figure 2. Features of PTSD addressed in the DSM-5 diagnostic criteria. This figure 
summarizes the symptoms of PTSD addressed by each criterion for PTSD diagnosis in the DSM-
5. Examples of PTSD symptoms for each criterion A through E are also provided. Adapted from 
(American Psychiatric Association, 2013). 
 
 
Risk Factors and Comorbidities 
Many risk factors for PTSD are psychosocial and can be categorized as 
pretraumatic, traumatic, or posttraumatic (Friedman, 2015d; Johnson et al., 2019). 
Examples of pretraumatic risk factors include female gender, age under 25, Hispanic 
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race, less than a college education, adverse life events, childhood trauma, and psychiatric 
disorders (Friedman, 2015d; Johnson et al., 2019; Steel et al., 2017). The main traumatic 
risk factor is experiencing severe trauma—the greater the severity of the experienced 
trauma, the greater the risk of developing PTSD (Friedman, 2015d; Johnson et al., 2019). 
Posttraumatic risk factors include poor social support and coping strategies, which along 
with experiencing severe trauma comprise the strongest risk factors (Friedman, 2015d; 
Johnson et al., 2019).  
PTSD is particularly prevalent in vulnerable populations (Hien et al., 2009). For 
example, non-combat-related PTSD was found highly prevalent in a vulnerable 
population of homeless adults in the metropolitan city of Boston, Massachusetts, with 68 
percent of participants (N = 306) having PTSD (Baggett, Campbell, Chang, Magid, & 
Rigotti, 2016). PTSD is also often comorbid with substance use disorders (SUDs) (Dore, 
Mills, Murray, Teesson, & Farrugia, 2012; Mills, Teesson, Ross, & Peters, 2006) and/or 
serious mental illness (SMI) (Goodman, Rosenberg, Mueser, & Drake, 1997; Grubaugh, 
Zinzow, Paul, Egede, & Frueh, 2011; Kessler, Sonnega, Bromet, Hughes, & Nelson, 
1995). In the case of PTSD and comorbid substance use, it is thought that the use of 
substances can help control the negative emotions associated with PTSD, and in doing so 
serves as positive reinforcement for continuing substance use (Chilcoat & Breslau, 1998; 
Jacobsen, Southwick, & Kosten, 2001). In the case of individuals with SMI, having 
schizophrenia, bipolar disorder, and/or major depression, for example, is often associated 
with stressful life events such as childhood trauma (Mueser et al., 2015; Steel et al., 
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2017), with rates of PTSD ranging from 25 to 48 percent in most populations of 
individuals with SMI (Grubaugh et al., 2011). 
 
Psychological Treatment Options  
Psychological treatment options for PTSD, displayed in Figure 3, have proved 
successful (Friedman, 2015b). In particular, the American Psychological Association 
clinical practice guideline “strongly recommends” cognitive behavioral therapy (CBT), a 
type of individual psychotherapy (American Psychiatric Association, 2013). Cognitive 
behavioral therapy helps individuals overcome the intrusion symptoms of unwanted and 
persistent thoughts, feelings, and images related to the traumatic event (Friedman, 
2015c). In doing so, individuals are less likely to rely on avoidance, which reduces the 
emotional impact of the traumatic event in the short term without helping individuals to 
overcome it (Friedman, 2015c). Prolonged exposure (PE) and cognitive processing 
therapy (CPT) are two of the most studied and powerful forms of CBT for PTSD 
(Friedman, 2015b). The goal of both of these types of CBT is the same as the goal of 
CBT; however, PE and CPT employ different strategies (Friedman, 2015b).  
 
Figure 3. Types of psychological treatment for PTSD. This diagram shows some of the 
different types of psychological treatment for PTSD. CPT and PE are two of the most studied and 
powerful forms of CBT, which is strongly recommended PTSD treatment by the APA. EMDR is 
another form of psychotherapy and is endorsed by the World Health Organization (World Health 
Organization, 2013). CBT = cognitive behavioral therapy; EMDR = eye movement 
desensitization and reprocessing; CPT = cognitive processing therapy; PE = prolonged exposure. 
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Prolonged exposure  
Prolonged exposure (PE) is a type of cognitive behavioral therapy with the goal of 
preventing a traumatic memory from evoking a negative emotional response, such as 
fear, stress, or anxiety (Foa, Hembree, & Rothbaum, 2007). To do so, prolonged exposure 
protocols make use of imaginal exposure and in vivo exposure (Friedman, 2015c; 
McLean, Asnaani, & Foa, 2015; Perrin, 2013). On behalf of the individual with PTSD, 
imaginal exposure requires recounting the traumatic experience out loud to a clinician so 
that he or she may help the patient process the traumatic experiences and dispel any false 
thoughts (Friedman, 2015c; McLean et al., 2015; Perrin, 2013). For example, after 
imaginal exposure, a patient who witnessed the death of a friend may arrive to the 
conclusion that “I did the best I could under the circumstances” over his or her previous 
belief that “I could have saved my friend if I were more competent” (McLean et al., 
2015). Patients’ accounts of their traumatic experiences are recorded so that they may 
listen and be reexposed to them for homework (McLean et al., 2015). 
In addition to imaginal exposure, in vivo exposure involves patients gradually 
encountering situations that are objectively safe but have been avoided for reminding 
them of the trauma (Friedman, 2015c; McLean et al., 2015; Perrin, 2013). In vivo 
exposure is generally accomplished as homework (Friedman, 2015c; McLean et al., 
2015). Prolonged exposure also involves some patient education regarding the nature of 
trauma, the utility of prolonged exposure, and breathing strategies to help with 
controlling fear (McLean et al., 2015). Prolonged exposure protocols range from 8 to 15 
sessions of 90 minutes (McLean et al., 2015).  
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The concurrent treatment of PTSD and substance use disorders using prolonged 
exposure (COPE) is a modified version of PE that also addresses substance use (Back et 
al., 2014). The COPE protocol includes PE to address PTSD and non-exposure-based 
CBT, such as relapse prevention therapy (RPT), to treat substance use (Back et al., 2014). 
Each of 12 total sessions integrates PTSD and SUD treatment with in vivo exposure 
taking place in sessions 3 to 11, imaginal exposure occurring in sessions 4 to 11, and 
substance use goals planned collaboratively between clinician and patient being 
addressed throughout (Back et al., 2014; Persson et al., 2017). Unlike with concurrent 
PTSD and SUD, there is no PE protocol tailored to treat PTSD and SMI in an integrated 
fashion.  
Cognitive processing therapy  
As with PE, cognitive processing therapy (CPT) is also a form of trauma-focused 
CBT (Friedman, 2015c; Galovski & Gloth, 2015; Galovski, Wachen, Chard, Monson, & 
Resick, 2015). Whereas PE focuses on repeatedly exposing patients to their trauma so 
that they may be helped to overcome the resulting negative emotions, CPT focuses on 
individuals’ interpretations and descriptions of their trauma (Friedman, 2015c; Galovski 
& Gloth, 2015; Galovski et al., 2015). Patients are instructed to document and share their 
thoughts and emotions surrounding their traumatic experiences so that clinicians can 
identify and help them confront false beliefs, self-blaming, and other negative thoughts or 
emotions related to the traumatic event (Friedman, 2015c). During the approximately 12 
sessions of CPT, clinicians facilitate cognitive restructuring by helping the patient 
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develop and practice strategies for overcoming unhelpful cognitions (Friedman, 2015c; 
Galovski & Gloth, 2015).  
Seeking Safety (SS) is a specific CPT protocol designed to improve PTSD and 
substance use disorder symptoms in individuals with PTSD and concurrent SUD (Back et 
al., 2014; Najavits, 2002; Najavits, Gallop, & Weiss, 2006). Just as sessions of the COPE 
protocol address PTSD and SUD, SS is also an integrated form of treatment with sessions 
addressing PTSD and SUD through CBT, specifically the teaching of “safe” coping skills 
for symptoms of both disorders (Najavits, 2002). Clinicians follow a manual and patients 
complete handouts in-session or as homework over the course of approximately 25 
sessions that are typically carried out weekly for an hour (Back et al., 2014; Najavits, 
2002). Regarding individuals with concurrent PTSD and SMI, there is no single CPT 
protocol that integrates the treatment of both comorbidities. 
Eye movement desensitization and reprocessing 
As Figure 3 shows, in addition to cognitive behavioral therapy (CBT), eye 
movement desensitization and reprocessing (EMDR) is another form of evidence-based 
psychological treatment for PTSD (Friedman, 2015c; Shapiro & Laliotis, 2015). Similar 
to PE and CPT, EMDR contains trauma-focused components (Friedman, 2015c), but it 
does not require recalling the traumatic event aloud for the purpose of coping with it 
(Friedman, 2015c; van den Berg et al., 2015). Rather, EMDR is predicated on the theory 
that traumatic memories are unprocessed, and the goal of EMDR is to facilitate the 
processing of these memories (Friedman, 2015c; Johnson et al., 2019; Shapiro & Laliotis, 
2015). First, the patient is told to recall the traumatic memory; then positive thoughts 
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related to oneself are stated out loud, helping the brain to reprogram the memory 
(Friedman, 2015c; Johnson et al., 2019; Shapiro & Laliotis, 2015). Next, the patient is 
asked to recall the traumatic memory once more while focusing on the clinician’s finger 
waving in front of his or her eyes 24 times (Friedman, 2015c; Johnson et al., 2019; 
Shapiro & Laliotis, 2015). Afterward, the patient rates his or her distress and agreement 
with the stated self-affirming cognitions before blocking out the memory in preparation 
for the next trial (Shapiro & Laliotis, 2015). These steps are repeated until the patient 
reports his or her distress as zero (Shapiro & Laliotis, 2015). In addition to following a 
clinician’s finger with both eyes, a patient may also be instructed to listen to clicks played 
from headphones and alternating between ears, as the actual eye movements are not as 
important as following the cognitive steps of recalling the memory, stating self-affirming 
thoughts, rating one’s distress, and blocking out the traumatic memory (de Bont, van 
Minnen, & de Jongh, 2013; Friedman, 2015c).  
 
Specific Aims 
There are three specific aims that this work addresses:  
(1) To provide background information on the types of psychological 
therapies available to treat PTSD in particularly vulnerable populations 
with concurrent SUD or SMI. 
(2) To present the findings of research studies that have evaluated the efficacy 
of various psychological treatment options for PTSD and SUD or SMI. 
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(3) To conclude which forms of psychotherapy appear the most effective in 
treating PTSD, SUD, and SMI outcomes. 
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PUBLISHED STUDIES 
 
Psychological Treatment for Concomitant PTSD and SUD  
 
The studies presented in this section are the key features and findings of 
randomized controlled trials (RCTs) that examined the efficacy of psychological 
treatment on PTSD in vulnerable populations, specifically individuals with PTSD and 
concurrent SUD. These studies were selected for their treatment of vulnerable 
populations and their ability to be carried out in community-based outpatient or inpatient 
settings serving primarily underserved populations. The studies meeting these criteria 
were used to determine the efficacy of either prolonged exposure (PE) or cognitive 
processing therapy (CPT) on PTSD and SUD outcomes.  
Prolonged exposure studies 
Table 1 presents five studies (all RCTs) that used PE to treat PTSD in individuals 
with concurrent PTSD and SUD. Each study is characterized by (1) recruitment strategy, 
(2) participant characteristics, (3) study protocol, and (4) treatment conditions.  
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Table 1. Key Features of Studies Using PE to Treat PTSD in Individuals With 
Concurrent PTSD and SUDa 
 
Coffey, Stasiewicz, Hughes, & Brimo (2006) 
Recruitment 
strategy 
 
N = 43 
 
Two outpatient substance use treatment programs in Buffalo, NY 
Participant 
characteristics  
PTSD (not stemming from combat) and alcohol dependence; low socioeconomic 
status; 65% Black/African American; 28% White; concurrent psychological 
impairments; participation in Alcoholics Anonymous was strongly encouraged but 
not required by the two clinics from which individuals were recruited  
Study protocol 2 laboratory sessions (outcomes measured) with 6 60-minute clinical sessions of 
imaginal exposure or relaxation in between 
Treatment 
conditions  
Group 1: Exposure. The clinical sessions consisted of imaginal exposure (i.e., 
telling the story of their trauma, sharing their emotions and cognitions 
surrounding the event) 
 
Group 2: Relaxation. The clinical sessions consisted of listening to a relaxing 
audiotape 
Coffey et al. (2016)  
Recruitment 
strategy 
N = 126 
 
“Unlocked” 6-week community residential SUD treatment facility located near 
moderately-sized city serving patients from rural counties 
Participant 
characteristics  
PTSD (not stemming from combat) and alcohol dependence; excluded on 
benzodiazepine use; 79% White; 19% Black/African American; 46% women; 48% 
with some post high school education; 80% with major depressive disorder 
Study protocol 9-12 60-minute sessions 
Treatment 
conditions  
Group 1: Participants received modified prolonged exposure (mPE) plus 
treatment as usual  
 
Group 2: Participants received mPE and a 90-minute trauma-focused 
motivational enhancement session (mPE + MET) prior to mPE (designed to 
improve study treatment retention) plus treatment as usual  
 
Group 3: Control. Participants received same amount of therapist 
contact, obtaining information on health-related topics (e.g., sleep, muscle 
relaxation, healthy eating, diabetes prevention or treatment adherence, etc.) plus 
treatment as usual 
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Table 1 (continued).  
 
Sannibale et al. (2013) 
Recruitment 
strategy 
N = 62 
 
Individuals recruited from “a range of services” provided in metropolitan Sydney, 
Australia 
Participant 
characteristics  
PTSD and alcohol use disorder; 47% recruited from drug and alcohol treatment 
services; 53% women; excluded on substance dependence (i.e., severe SUD) 
Study protocol 12 weekly 90-minute sessions 
Treatment 
conditions  
Group 1: Participants received AUD treatment plus a treatment protocol that 
integrated CBT for AUD and exposure-based CBT for PTSD 
 
Group 2: Participants received AUD treatment plus supportive counseling  
Mills et al. (2012) 
Recruitment 
strategy 
N = 103 
 
Provider referrals in greater Sydney, Australia  
Participant 
characteristics  
PTSD and substance dependence (i.e., severe SUD); 73% screened positive for 
borderline personality disorder 
Study protocol 13 weekly 90-minute sessions 
Treatment 
conditions  
Group 1: COPE + TAU. Participants received COPE and engaged in treatment 
as usual (TAU) for substance dependence (e.g., outpatient counseling, 
pharmacotherapies, etc.) 
 
Group 2: TAU. Participants received treatment as usual for SUD, alone 
Ruglass et al. (2017) 
Recruitment 
strategy 
N = 110 
 
Ads and outpatient referrals in New York City, NY 
Participant 
characteristics  
PTSD (full or subthreshold) and SUD; “racially/ethnically diverse” population; 
polysubstance-dependent 
Study protocol 12 weekly 90-minute sessions 
Treatment 
conditions  
Group 1: Active treatment 1. Participants received COPE 
 
Group 2: Active treatment 2. Participants received relapse prevention therapy, an 
evidence-based form of CBT for substance use disorders, alone  
 
Group 3: Control. Participants completed self-report measures and were 
monitored for their general safety; however, they did not receive any study 
treatment for SUD or PTSD (after the 12-week study period, study staff referred 
individuals to outpatient treatment opportunities) 
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aThis table shows the key features of five RCTs studying the effect of PE on PTSD and substance 
use outcomes in individuals receiving treatment as usual for SUD in a community or low-income 
health care setting. PE = prolonged exposure; PTSD = posttraumatic stress disorder; SUD = 
substance use disorder; mPE = modified prolonged exposure; MET = motivational enhancement; 
AUD = alcohol use disorder; CBT = cognitive behavioral therapy; COPE = concurrent treatment 
of PTSD and substance use disorders using prolonged exposure; TAU = treatment as usual. 
 
Prolonged exposure findings 
 
 Outcomes of interest with respect to all of the studies described in Table 1 involve 
PTSD symptom severity and substance use.  
Coffey and colleagues compared the effects of prolonged exposure with 
relaxation (Coffey, Stasiewicz, Hughes, & Brimo, 2006). Individuals in both groups 
provided scores on alcohol craving and subjective level of distress after experiencing 
“trauma and alcohol” (i.e., after watching a video in which they described their own 
trauma and then were provided alcohol) (Coffey et al., 2006). Individuals in the 
prolonged exposure group fared significantly better than individuals in the relaxation 
group with respect to both alcohol craving (p ≤ 0.05) and distress (p ≤ 0.001) over the 
study period (Coffey et al., 2006). Thus, exposure therapy helped more than relaxation in 
significantly reducing distress and alcohol craving (Coffey et al., 2006). The researchers 
did not follow up these outcomes after the end of treatment (Coffey et al., 2006). 
In another study, Coffey et al. (2016) were interested in the efficacy of prolonged 
exposure with respect to a combination of prolonged exposure and motivational 
enhancement and a control group that received healthy lifestyle sessions. These authors 
evaluated PTSD symptom severity, alcohol craving, and proportion of past 90 days 
abstinent with respect to alcohol and drugs in participants at baseline, end-of-treatment, 
and various points of follow-up (3 months and 6 months), allowing for the observation of 
 17 
any sustaining effects (Coffey et al., 2016). After examination of between-group 
differences, they found that at the end of treatment and at the 3-month follow-up, 
individuals in both treatment groups did significantly better (p ≤ 0.05) with respect to 
PTSD symptom severity compared with individuals in the control (Coffey et al., 2016). 
At the 6-month follow-up, however, only individuals in Group 1 (prolonged exposure 
alone) did significantly better than individuals in the control; the improvement seen by 
Group 2 individuals (prolonged exposure + motivational enhancement) was not 
significantly better than the improvement seen in the control (Group 3) (Coffey et al., 
2016). With respect to alcohol craving, the researchers found a decline in participant 
scores throughout the study and into the follow-up period that did not differ between the 
three groups (Coffey et al., 2016). Also, the researchers found that the proportion of days 
abstinent for drugs and for alcohol did not differ significantly between either of the two 
treatment groups compared with the control (Coffey et al., 2016). Thus, prolonged 
exposure alone or in combination with motivational enhancement improved PTSD 
symptoms significantly, and these improvements were maintained at 3 months follow-up 
(Coffey et al., 2016). At 6 months, individuals in Group 1 still fared significantly better 
than individuals in the control group, although scores were substantially lower in all three 
groups (Coffey et al., 2016). With respect to substance use outcomes, alcohol craving 
declined and proportion of days abstinent with respect to alcohol and drugs increased, but 
no group fared significantly better than the other group at any time point (Coffey et al., 
2016). 
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Sannibale et al. (2013) were interested in comparing the effects of a treatment 
protocol that provided CBT for alcohol use disorder and PE for PTSD. Specifically, they 
randomly assigned participants to receive alcohol use disorder (AUD) treatment plus 
either integrated CBT for PTSD symptoms and alcohol consumption (Group 1) or 
supportive counseling (Group 2) (Sannibale et al., 2013). Outcomes were assessed twice 
during the study period (at baseline and at the end of treatment) and at two follow-up 
points (5 months and 9 months posttreatment) (Sannibale et al., 2013). Examining 
between-group differences, the researchers found that PTSD symptom severity improved 
from baseline and remained low throughout the follow-up period; however, there were no 
significant differences between groups (Sannibale et al., 2013). Only when Group 1 
participants engaged in at least one session of exposure therapy were they significantly 
more likely to have a reduction in PTSD symptom severity from baseline to 9 months 
follow-up compared with Group 2 participants (odds ratio [OR]: 4.05; 95% confidence 
interval [CI]: 1.78, 9.20) (Sannibale et al., 2013). Individuals in Group 2 did not 
experience a significant decrease in PTSD symptoms (Sannibale et al., 2013). With 
respect to alcohol consumption, the researchers found that the number of drinks per 
drinking day dropped from baseline and remained low throughout the follow-up period; 
at 5 months follow-up, this difference was significant (p = 0.05), with participants in 
Group 1 reporting a significantly lower number compared with individuals in Group 2 
(Sannibale et al., 2013). Also, the proportion of past 90 days abstinent increased from 
baseline in both groups, but there were no significant between-group differences at any 
time point (Sannibale et al., 2013). Thus, Sannibale et al. (2013) found that PTSD 
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symptoms improved and remained improved in both groups; however, when participants 
in Group 1 also received at least one session of prolonged exposure, they were 
significantly more likely to improve in PTSD symptom severity compared with Group 2 
participants from baseline to 9 months follow-up. In addition, with respect to alcohol 
consumption, there were no significant differences between groups at any time points 
during or following treatment, but the number of drinks per drinking day and proportion 
of days abstinent improved in both groups, and this improvement was sustained at both 
points of follow-up (Sannibale et al., 2013).  
In a study by Mills et al. (2012), the researchers were interested in the effect of 
concurrent treatment of PTSD and substance use disorders using prolonged exposure 
(COPE) compared with substance use treatment as usual on PTSD symptom severity and 
severity of substance use. Outcomes were measured at baseline and three time points 
post-baseline: 6 weeks, 3 months, and 9 months (Mills et al., 2012). With respect to 
PTSD, Mills et al. (2012) examined within-group differences and found that the PTSD 
symptom severity declined significantly from baseline to 9 months follow-up in both 
groups (p < 0.001). Between-group differences from baseline to 9-month follow-up also 
showed that the drop in PTSD symptom severity was significantly greater for individuals 
in the treatment group compared with the control (mean difference: -16.09; 95% CI: -
29.00, -3.19) (Mills et al., 2012). To describe individuals’ substance use severity, Mills et 
al. (2012) again examined between-group differences and measured (1) the number of 
substance use dependence criteria met and (2) the prevalence of substance use abstinence. 
They found that the prevalence of abstinence did not differ significantly between the 
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treatment and control groups from baseline to 9 months post-baseline (Mills et al., 2012). 
Also, within-group percentage increases in substance use abstinence were not significant 
from baseline to 9 months follow-up in either group (Mills et al., 2012). With respect to 
severity of substance use (as measured by number of substance use dependence criteria 
met), Mills et al. (2012) found that this value decreased significantly (p < 0.001) within 
both groups from baseline to the 9-month follow-up; however, the between-group 
difference in number of dependence criteria met at the 9-month follow-up was not 
significant. Thus, Mills et al. (2012) found that COPE produced more significant effects 
on PTSD compared with substance use severity.  
Ruglass and colleagues also examined the effect of COPE on PTSD and substance 
use (Ruglass et al., 2017). They assigned participants to receive COPE (Group 1) or 
relapse prevention therapy (RPT) for substance use, an evidence-based treatment (Group 
2) (Ruglass et al., 2017). In addition, approximately one-third of the study population was 
assigned to a control group that provided the same self-report measures as the 
participants receiving treatment but did not receive any study treatment for PTSD or SUD 
(Ruglass et al., 2017). At baseline, end-of-treatment, and three follow-up points (1, 2, and 
3 months after end-of-treatment), the researchers measured PTSD symptom severity 
(Ruglass et al., 2017). They also measured SUD outcomes through a self-report of 
primary substance use in the past 30 days (Ruglass et al., 2017). With respect to PTSD 
symptom severity, Ruglass et al. (2017) found that individuals in Group 1 and in Group 2 
both improved significantly at the 1-month follow-up (p < 0.001 for both groups) and at 
the 3-month follow-up (p < 0.001 for both groups) compared with their baseline PTSD 
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symptom severity. Examining between-group differences, the authors found that PTSD 
symptom severity did not vary significantly between the two active treatment groups at 
any of the three follow-up points (Ruglass et al., 2017). Both treatment groups also 
showed significant reductions at the 1-month (p < 0.001 for both groups) and 3-month (p 
< 0.001 for both groups) follow-ups relative to baseline on past 30-day primary substance 
use (Ruglass et al., 2017). As was the case with PTSD symptom severity and between-
group differences, the authors found no significant differences in past 30-day substance 
use between individuals in either of the two active treatment groups at any of the three 
follow-up points (Ruglass et al., 2017). Thus, Ruglass et al. (2017) found that COPE and 
treatment as usual were both effective at improving PTSD and substance use outcomes 
through follow-up compared with the control group (Ruglass et al., 2017). However, 
among those participants with full PTSD compared with subthreshold PTSD, reduction of 
PTSD symptom severity was significantly greater in individuals who received COPE 
compared with RPT (p < 0.05) (Ruglass et al., 2017).  
Table 2 displays the percentage changes in each of the aforementioned PTSD- and 
SUD-specific variables over the course of each of the five RCTs. The impact of treatment 
assignment on these variables can provide a better idea of the effect of PE on PTSD and 
substance use outcomes in individuals with PTSD and SUD. In most cases, depending on 
the data provided, a percentage change was calculated from baseline to the end of 
treatment as well as from baseline to the last point of follow-up.   
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Table 2. Percentage Changes in PTSD and SUD Outcomes in Studies Using PEa 
 
Coffey, Stasiewicz, Hughes, & 
Brimo (2006) 
 Lab session 1 to lab session 2 
Distress1 Exposure -65%b 
Relaxation  -5% 
Alcohol craving2 Exposure -87%c 
Relaxation  -18% 
1 Measured using the Subjective Unit of Distress Scale (SUDS); participants responded 0 to 100 
(highest SUDS level)  
2 Participants responded to “I crave a drink right now” on a scale from 0 to 10 (very strong craving 
to drink alcohol) 
b Used to calculate the average percentage change in PTSD outcomes as a result of PE 
alongside TAU for PTSD in Appendix 
c Used to calculate the average percentage change in substance use outcomes as a result of PE 
alongside TAU for PTSD in Appendix 
Coffey et al. (2016)  Baseline to end-of-
treatment 
Baseline to 6-month 
follow-up 
PTSD symptom severity1 Exposure -67% -66%b 
Exposure +  -63% -63% 
Control -46% -48% 
Alcohol craving2  Exposure -33% -33%c 
Exposure +  -34% -45% 
Control -19% -26% 
Alcohol use (proportion of past 
90 days abstinent)3 
Exposure Not given  +105%c 
Exposure +  Not given  +76% 
Control Not given  +79% 
Drug use (proportion of past 
90 days abstinent)3  
Exposure Not given  +81%c 
Exposure +  Not given  +102% 
Control Not given  +54% 
1 Measured using Impact of Event Scale – Revised (IES-R); higher scores indicate more distress 
2 Measured using Alcohol Craving Questionnaire – Now (ACQ-Now); higher scores indicate 
greater alcohol cravings 
3 Measured using Time Line Follow-Back (TLFB) method; objective measurements were also 
taken to validate self-report 
b Used to calculate the average percentage change in PTSD outcomes as a result of PE 
alongside TAU for PTSD in Appendix 
c Used to calculate the average percentage change in substance use outcomes as a result of PE 
alongside TAU for PTSD in Appendix 
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Table 2 (continued).  
 
Sannibale et al. (2013)  Baseline to end-of-
treatment 
Baseline to 9-month 
follow-up 
PTSD symptom severity1 Integrated 
CBT 
-37% -36%b 
Counseling -31% -39% 
Alcohol use (proportion of past 
90 days abstinent)2 
Integrated 
CBT 
+180% +175%c 
Counseling +369% +273% 
Number of drinks per drinking 
day2 
Integrated 
CBT 
-44% -48%c 
Counseling -45% -51% 
1 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores indicate more 
severe PTSD 
2 Measured using Time Line Follow-Back (TLFB) method 
b Used to calculate the average percentage change in PTSD outcomes as a result of integrated 
PE and SUD treatment for PTSD in Appendix 
c Used to calculate the average percentage change in substance use outcomes as a result of 
integrated PE and SUD treatment for PTSD in Appendix 
Mills et al. (2012)  Baseline to 9 months post-baseline 
PTSD symptom severity1 COPE -42%b 
Treatment as 
usual 
-25% 
Number of substance use 
dependence criteria met2 
COPE -57%c 
Treatment as 
usual 
-47% 
Substance use abstinence 
prevalence2  
COPE +18%c 
Treatment as 
usual 
+27% 
1 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
2 Measured using Composite International Diagnostic Interview (CIDI) 
b Used to calculate the average percentage change in PTSD outcomes as a result of integrated 
PE and SUD treatment for PTSD in Appendix 
c Used to calculate the average percentage change in substance use outcomes as a result of 
integrated PE and SUD treatment for PTSD in Appendix 
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Table 2 (continued).  
 
Ruglass et al. (2017)  Baseline to end-of-
treatment 
Baseline to 3-month 
follow-up 
PTSD symptom severity1 COPE -32% -49%b 
Treatment as 
usual 
-47% -50% 
Control -10% Not given, as control 
participants were not 
followed up 
Past 30-day primary substance 
use2 
COPE -36% -56%c 
Treatment as 
usual 
-77% -79% 
Control -37% Not given 
1 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
2 Measured using Addiction Severity Index – Lite (ASI-Lite) at baseline and follow-up, and 
Substance Use Inventory (SUI) during treatment 
b Used to calculate the average percentage change in PTSD outcomes as a result of integrated 
PE and SUD treatment for PTSD in Appendix 
c Used to calculate the average percentage change in substance use outcomes as a result of 
integrated PE and SUD treatment for PTSD in Appendix 
aThis table shows the percentage changes in PTSD and SUD outcomes from baseline to the end 
of treatment and last point of follow-up in studies (described in Table 1) using PE to treat PTSD 
in individuals with concurrent PTSD and SUD. PTSD = posttraumatic stress disorder; SUD = 
substance use disorder; PE = prolonged exposure; Exposure + = exposure plus motivational 
enhancement; CBT = cognitive behavioral therapy; COPE = concurrent treatment of PTSD and 
substance use disorders using prolonged exposure. 
 
 
Cognitive processing therapy studies 
 
Table 3 presents six studies (five primary analyses of RCTs and one secondary 
analysis of a RCT) that used CPT to treat PTSD in individuals with concurrent PTSD and 
SUD. Each study is characterized by (1) recruitment strategy, (2) participant 
characteristics, (3) study protocol, and (4) treatment conditions.  
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Table 3. Key Features of Studies Using CPT to Treat PTSD in Individuals With 
Concurrent PTSD and SUDa 
 
Hien, Cohen, Miele, Litt, & Capstick (2004)  
Recruitment 
strategy 
N = 107 
 
Ads requesting participants for a study about trauma and addiction or referrals 
from substance use treatment programs in a major metropolitan area  
Participant 
characteristics  
Presence of a lifetime traumatic event; PTSD (full or subthreshold); substance 
dependence (i.e., severe SUD); women; urban; low-income; participating in 
treatment programs or treatment-seeking 
Study protocol 2 sessions per week for 12 weeks; 60-minute sessions 
Treatment 
conditions  
Group 1: Participants received Seeking Safety 
 
Group 2: Participants received CBT for substance dependence alone 
 
Group 3: Control. Participants received standard community care; that is, they 
were not offered either active study treatment, but were referred to other common 
forms of substance abuse treatment (the same forms of treatment also available 
to those in the active treatment groups) 
Hien et al. (2009)  
Recruitment 
strategy 
N = 353 
 
Ads via brochures, fliers, newspaper, and other print media; referrals from 
community treatment program staff around US (urban and suburban settings in 
Western, Midwestern, Northeastern, and Southeastern US) 
Participant 
characteristics  
PTSD (full or subthreshold); presence of a lifetime traumatic event; substance 
dependence (i.e., severe SUD); women; enrolled in outpatient community-based 
substance abuse treatment programs in US; 45% White; 34% Black/African 
American; most common substance use disorders: cocaine (greatest), alcohol, 
marijuana, opioid (least) 
Study protocol 2 sessions per week for 6 weeks 
Treatment 
conditions  
Group 1: SS. Participants received Seeking Safety plus standard substance 
abuse treatment from a community treatment program 
 
Group 2: Control. Participants received health education plus standard 
substance abuse treatment from a community treatment program 
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Table 3 (continued). 
 
Najavits, Gallop, & Weiss (2006) 
Recruitment 
strategy 
N = 33 
 
Ads via fliers at bus stops, and active recruitment from “local” (unclear where in 
US) clinics, hospitals, schools, and clinicians 
Participant 
characteristics  
PTSD; SUD (94% with substance dependence; i.e., severe SUD); adolescent 
girls (average age of 16 years-old); substance use in past 60 days  
Study protocol 25 sessions over 3 months; 50-minute sessions 
Treatment 
conditions  
Group 1: SS. Participants received Seeking Safety plus treatment as usual for 
substance dependence 
 
Group 2: TAU. Participants received treatment as usual for substance 
dependence 
Ruglass, Hien, Hu, & Campbell (2014)  
Recruitment 
strategy 
N = 141; a subset of the Hien et al. (2009) sample (N = 353) that reported 
stimulant (cocaine or amphetamine) use  
 
Ads via brochures, fliers, newspaper, and other print media; referrals from 
community treatment program staff around US (urban and suburban settings in 
Western, Midwestern, Northeastern, and Southeastern US) 
Participant 
characteristics  
PTSD (full or subthreshold); presence of a lifetime traumatic event; women; 
enrolled in outpatient community-based substance abuse treatment programs in 
US; past-month stimulant use 
Study protocol 2 sessions per week for 6 weeks 
Treatment 
conditions  
Group 1: SS. Participants received Seeking Safety plus standard substance 
abuse treatment from a community treatment program 
 
Group 2: Control. Participants received health education plus standard 
substance abuse treatment from a community treatment program 
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Table 3 (continued).  
 
McGovern, Lambert-Harris, Alterman, Xie, & Meier (2011) 
Recruitment 
strategy 
N = 53 
 
Seven community-based, intensive outpatient or methadone maintenance 
programs in New Hampshire, Vermont, and Connecticut  
Participant 
characteristics  
PTSD and SUD; receiving outpatient addiction services (all new admissions to 
community addiction treatment programs); 57% women; 91% White  
Study protocol 1 session per week for 12-14 weeks; 50-minute sessions 
Treatment 
conditions  
Group 1: Integrated CBT + standard care. Participants received an integrated 
treatment protocol of CBT for PTSD and substance use in addition to standard 
care for substance use in the form of either intensive outpatient or methadone 
maintenance services  
 
Group 2: Individual addiction counseling + standard care. Participants 
received addiction counseling in addition to standard care for substance use in 
the form of either intensive outpatient or methadone maintenance services  
Zlotnick, Johnson, & Najavits (2009) 
Recruitment 
strategy 
N = 49 
 
Residential substance abuse treatment program in minimum security wing of a 
women’s prison  
Participant 
characteristics  
PTSD (including subthreshold); substance-dependent in month prior to entering 
prison; incarcerated women scheduled to be released within 12-16 weeks 
Study protocol During incarceration SS was carried out ~3 times per week for 6-8 weeks; 90-
minute group sessions (3-5 women per group) 
 
After incarceration: weekly, individual 60-minute sessions for 12 weeks 
Treatment 
conditions  
Group 1: SS + TAU. Participants received SS and treatment as usual (TAU) 
where the TAU program was similar to other state prison substance use 
programs that teach relapse prevention and offer substance use education 
 
Group 2: TAU. Participants received only TAU, which was similar to other state 
prison substance use programs that teach relapse prevention and offer 
substance use education (consisted of group and individual treatment) 
aThis table shows the key features of six studies (five primary analyses and one secondary 
analysis of RCTs) examining the effect of CPT on PTSD and substance use outcomes in 
individuals receiving treatment as usual for SUD in a community or low-income health care 
setting. CPT = cognitive processing therapy; PTSD = posttraumatic stress disorder; SUD = 
substance use disorder; CBT = cognitive behavioral therapy; SS = Seeking Safety; TAU = 
treatment as usual. 
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Cognitive processing therapy findings 
 
Outcomes of interest with respect to all of the studies described in Table 3 involve 
PTSD symptom severity and substance use. 
Hien and coworkers examined the efficacy of CPT on PTSD and substance use 
severity (Hien, Cohen, Miele, Litt, & Capstick, 2004). One group (Group 1) received 
Seeking Safety (SS), a studied CPT protocol for PTSD and SUD in individuals comorbid 
for both, and the other group (Group 2) received CBT in the form of relapse prevention 
therapy for substance dependence alone (Hien et al., 2004). In addition to the two 
treatment groups, a group of participants receiving community care and neither of the two 
active study treatments served as the control group (Group 3) (Hien et al., 2004). The 
researchers found that individuals in both active treatment groups fared significantly 
better at the end of treatment than individuals in Group 3 with respect to PTSD symptom 
severity (Group 1: p < 0.01; Group 2: p < 0.01) and substance use severity (Group 1: p < 
0.001; Group 2: p < 0.01) (Hien et al., 2004). These gains remained at the 6-month 
follow-up such that individuals in Groups 1 and 2 still scored significantly better with 
respect to PTSD symptom severity (Group 1: p < 0.01; Group 2: p < 0.01) and substance 
use severity (Group 1: p < 0.05; Group 2: p < 0.01) compared with individuals in Group 3 
receiving only community care (Hien et al., 2004). By the 9-month follow-up, individuals 
in both active treatment groups still had sustained improvements in PTSD symptom and 
substance use severity (Hien et al., 2004). With respect to PTSD symptom severity, 
individuals in both treatment groups had significantly better outcomes at follow-up 
compared with those in the control (Group 1: p < 0.05; Group 2: p < 0.01) (Hien et al., 
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2004). With respect to substance use severity, however, the improvements were 
significantly more sustained for individuals receiving relapse prevention therapy (p < 
0.05) compared with those receiving the Seeking Safety protocol (Hien et al., 2004).  
A study by Hien et al. (2009) also examined the efficacy of CPT on PTSD 
symptom severity and substance use. One group (Group 1) received Seeking Safety in 
addition to substance abuse treatment from a community treatment program, and the 
second group (Group 2) received health education in addition to the same community 
substance abuse treatment program (Hien et al., 2009). The outcomes of interest were 
measured at baseline, end-of-treatment, and three points of follow-up (3 months, 6 
months, and 12 months posttreatment) and consisted of PTSD symptom severity, 
measured with a clinician-administered tool (CAPS-5) and a self-reported tool 
(Posttraumatic Stress Disorder Symptom Scale – Self Report, PSS-SR), and past 7-day 
drug or alcohol use (Hien et al., 2009). With respect to self-reported posttraumatic 
symptoms (measured using the PSS-SR), the researchers found that after week one of the 
six-week intervention period, the mean PSS-SR value for individuals receiving Seeking 
Safety decreased significantly more quickly than in individuals receiving education (p = 
0.05) (Hien et al., 2009). During the follow-up period, the mean PSS-SR values 
continued to decrease for both groups; however, the rate of decrease was significantly 
slower than the rate of decrease during the intervention period (p < 0.01) (Hien et al., 
2009). With respect to PTSD symptom severity measured with CAPS-5, the researchers 
found no treatment effect (Hien et al., 2009). Although scores decreased from baseline to 
the end of treatment and these decreases continued during the follow-up period, there was 
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no significant difference in scores between individuals in Group 1 compared with 
individuals in Group 2 (Hien et al., 2009). The researchers also found that there was no 
treatment effect on past 7-day drug or alcohol use (Hien et al., 2009). Throughout the 
trial, abstinence rates were not significantly different between the two treatment groups 
(Hien et al., 2009). Whereas treatment assignment did not significantly impact abstinence 
rates, Hien et al. (2009) found a significant effect on past 7-day drug or alcohol use from 
abstinence levels at baseline (p < 0.001) and from the study site at which all study 
procedures were carried out (p < 0.001). 
Najavits et al. (2006) studied the effect of Seeking Safety on PTSD symptom 
severity and substance use with two groups. One group received Seeking Safety in 
addition to treatment as usual for substance use, and the other group received treatment as 
usual alone (Najavits et al., 2006). Outcomes of interest were measured at baseline, end-
of-treatment, and 3 months follow-up (Najavits et al., 2006). PTSD symptom severity 
was addressed by measuring PTSD cognitions with the World Assumptions Scale, and 
trauma-related symptoms were evaluated with a trauma symptom checklist (Najavits et 
al., 2006). Substance use severity was measured using the Personal Experiences 
Inventory (PEI), which addresses both chemical dependence and psychosocial problems 
associated with substance use (Najavits et al., 2006). With respect to PTSD symptom 
severity, Najavits et al. (2006) found that individuals in the Seeking Safety group fared 
significantly better across time on the PTSD cognition related to benevolence compared 
with individuals receiving treatment as usual (p < 0.05). Scores on self-worth and world 
meaning, however, were not significantly different across time (Najavits et al., 2006). 
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Similarly, individuals receiving Seeking Safety fared significantly better across time 
compared with individuals in treatment as usual with respect to the trauma-related 
symptoms of sexual concerns (p < 0.05) and sexual distress (p < 0.05) (Najavits et al., 
2006). The other trauma-related symptoms for which no significant difference was found 
between groups were anxiety, anger, sexual preoccupation, depression, PTSD, fantasy 
dissociation, overt dissociation, and dissociation (Najavits et al., 2006). With respect to 
substance use, the authors found that individuals in the Seeking Safety group fared 
significantly better across time than those receiving treatment as usual in 7 of 10 
subcategories of the PEI assessing chemical dependence: effects from drug use (p < 
0.01), social benefits of drug use (p < 0.01), polydrug use (p < 0.05), psychological 
benefits of drug use (p < 0.05), transitional drug use (p < 0.05), preoccupation with drugs 
(p < 0.01), and loss of control (p < 0.01) (Najavits et al., 2006). The remaining 3 
subcategories (personal consequences of drug use, social-recreational drug use, and 
personal involvement with chemicals) were not significantly different across time 
between groups (Najavits et al., 2006). On the variables of the PEI assessing psychosocial 
problems associated with drug use (psychological disturbance, peer chemical 
environment, absence of goals, family estrangement, sibling chemical use, spiritual 
isolation, rejecting convention, negative self-image, and family pathology), no significant 
differences between groups were found across time (Najavits et al., 2006). Thus, the 
authors concluded that improvements related to PTSD symptom severity and substance 
use favored individuals receiving Seeking Safety and treatment as usual over individuals 
receiving treatment as usual alone (Najavits et al., 2006). 
 32 
In another study, researchers compared the effects of Seeking Safety (SS) and 
education on PTSD and substance use outcomes in a population of women with PTSD 
and stimulant (cocaine or amphetamine) use (Ruglass, Hien, Hu, & Campbell, 2014). 
Outcomes of interest were measured at baseline, end-of-treatment, 3 months follow-up, 6 
months follow-up, and 12 months follow-up for PTSD symptom severity and past 30-day 
stimulant use (Ruglass et al., 2014). Whereas the CAPS PTSD symptom severity score 
decreased in both groups and remained lower than baseline through the follow-up period, 
at the 6-month follow-up Ruglass et al. (2014) found a significant between-group 
difference for the PTSD severity in individuals receiving Seeking Safety compared with 
those receiving education (p = 0.05). The results showed that the Seeking Safety group 
scored significantly lower (Ruglass et al., 2014). Past 30-day stimulant use also decreased 
in both groups; however, only at the end of treatment was the decrease achieved by 
individuals in the Seeking Safety group significantly different from the decrease attained 
by individuals receiving women’s health education (p = 0.05) (Ruglass et al., 2014). 
Hence Ruglass et al. (2014) showed that improvements in PTSD symptom severity and 
stimulant use were attainable from SS and from education. The gains achieved by those 
who received SS were significantly greater than those achieved by individuals receiving 
health education at the 6-month follow-up for PTSD symptom severity and at the end of 
treatment for stimulant use (Ruglass et al., 2014).  
A study by McGovern and colleagues compared the effect of a non-Seeking 
Safety, integrated PTSD-SUD cognitive processing therapy with individual addiction 
counseling in women with PTSD and SUD who participated in outpatient programs for 
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substance use, such as an outpatient methadone maintenance program (McGovern, 
Lambert-Harris, Alterman, Xie, & Meier, 2011). Outcomes of interest were measured at 
baseline, 3 months post-baseline, and 6 months post-baseline and consisted of PTSD 
symptom severity, drug problem severity, alcohol problem severity, and past 90-day drug 
use (McGovern et al., 2011). With respect to PTSD symptom severity, the researchers 
found a significant treatment effect in that individuals receiving integrated CBT fared 
significantly better across time than individuals receiving addiction counseling alone (p = 
0.04) (McGovern et al., 2011). PTSD symptom severity decreased significantly in both 
groups over time (p = 0.00) (McGovern et al., 2011). With respect to substance use, 
McGovern et al. (2011) showed that drug problem severity and alcohol problem severity 
improved significantly in both groups over time (p = 0.00). Also, with respect to past 90-
day drug use, individuals receiving integrated CBT fared significantly better across time 
than those who received addiction counseling alone (p = 0.01) (McGovern et al., 2011).  
Similar to the work by Najavits et al. (2006), a study by Zlotnick, Johnson, and 
Najavits (2009) compared Seeking Safety (Group 1) with treatment as usual (Group 2) 
for its effect on PTSD symptom severity and substance use in women. Outcomes related 
to PTSD and substance use were measured at baseline, end-of-treatment, 3 months 
follow-up, and 6 months follow-up (Zlotnick, Johnson, & Najavits, 2009). With respect 
to PTSD symptom severity, the researchers found that women in both groups improved 
significantly from baseline to the end of treatment (Group 1: p ≤ 0.05; Group 2: p ≤ 0.01), 
from baseline to 3 months follow-up (p < 0.01 for both groups), and from baseline to 6 
months follow-up (p < 0.01 for both groups) (Zlotnick et al., 2009). In addition, there 
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were no between-group differences in PTSD symptom severity; CAPS scores did not 
differ significantly between individuals who received Seeking Safety and those who did 
not at any time point at which outcomes were measured throughout the study (Zlotnick et 
al., 2009). With respect to drug problem severity, women in both groups improved 
significantly on the ASI drug score from baseline to the 3-month follow-up (p ≤ 0.01 for 
both) and from baseline to the 6-month follow-up (p ≤ 0.01 for both) (Zlotnick et al., 
2009). With respect to alcohol problem severity, women who received treatment as usual 
improved significantly on the ASI alcohol score from baseline to the 3-month follow-up 
(p ≤ 0.05) (Zlotnick et al., 2009). However, there were no significant between-group 
differences for drug problem severity or alcohol problem severity at any time point 
(Zlotnick et al., 2009). Thus, the authors found no significant between-group differences 
in PTSD or substance use outcomes at any time point in this study (Zlotnick et al., 2009). 
Table 4 displays the percentage changes in each of the aforementioned PTSD- and 
SUD-specific variables over the course of each of the six studies. The impact of treatment 
assignment on these variables can provide a better idea of the effect of CPT on PTSD and 
substance use outcomes in individuals with PTSD and SUD. In most cases, depending on 
the data provided, a percentage change was calculated from baseline to the end of 
treatment as well as from baseline to the last point of follow-up. 
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Table 4. Percentage Changes in PTSD and SUD Outcomes in Studies Using CPTa  
 
Hien, Cohen, Miele, Litt, & 
Capstick (2004) 
 Baseline to end-of-
treatment 
Baseline to 9-month 
follow-up 
PTSD symptom severity1 Seeking Safety -21% -24%b 
Relapse Prevention -27%  -32% 
Community Care -8% -11% 
Substance use severity2 Seeking Safety n/a n/a 
Relapse Prevention n/a n/a 
Community Care n/a n/a 
1 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
2 Substance use severity is a composite of scores from the Substance Use Inventory (SUI), 
Clinical Global Impression (CGI) Scale, and Structured Clinical Interview for DSM (SCID); raw 
scores were not given so percentage changes from baseline to end-of-treatment and 9-month 
follow-up could not be calculated 
b Used to calculate the average percentage change in PTSD outcomes as a result of CPT for 
PTSD in Appendix 
Hien et al. (2009)  Baseline to end of 
intervention period 
Baseline to end of 
follow-up period  
PTSD symptom severity1 Seeking Safety -28% -34%b 
Women’s Health 
Education 
-26% -30% 
PTSD symptom severity2 Seeking Safety -49% -61%b 
Women’s Health 
Education 
-49% -58% 
Past 7-day drug or alcohol 
use3 
Seeking Safety -53% -18%c 
Women’s Health 
Education 
-51% -6% 
1 Measured using Posttraumatic Stress Disorder Symptom Scale – Self Report (PSS-SR); higher 
scores indicate greater frequency and intensity of PTSD symptoms  
2 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
3 Measured using the Substance Use Inventory (SUI); objective measurements were also taken 
to validate self-report 
b Used to calculate the average percentage change in PTSD outcomes as a result of CPT for 
PTSD in Appendix 
c Used to calculate the average percentage change in substance use outcomes as a result of 
CPT for PTSD in Appendix 
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Table 4 (continued).  
 
Najavits, Gallop, & Weiss 
(2006) 
 Baseline to end-of-
treatment 
Baseline to 3-month 
follow-up 
PTSD cognitions1  Seeking Safety n/a n/a 
Treatment as usual n/a n/a 
Trauma-related 
symptoms2 
Seeking Safety n/a n/a 
Treatment as usual n/a n/a 
Substance use3  Seeking Safety n/a n/a 
Treatment as usual n/a n/a 
1 Assessed using World Assumptions Scale (WAS); higher scores indicate more positive PTSD 
cognitions related to, for example, self-worth, benevolence of people, and benevolence of the 
impersonal world; raw scores were not given for all the variables addressed so percentage 
changes from baseline to end-of-treatment and 3-month follow-up could not be calculated 
2 Assessed using Trauma Symptom Checklist for Children (TSCC); higher scores indicate greater 
trauma-related symptoms; raw scores were not given for all the variables addressed so 
percentage changes from baseline to end-of-treatment and 3-month follow-up could not be 
calculated 
3 Assessed using Personal Experiences Inventory (PEI), which contains a “chemical involvement" 
section and a psychosocial problem severity section; higher scores indicate greater chemical 
involvement and psychosocial problem severity, respectively; raw scores were not given for all 
the variables addressed in each section so percentage changes from baseline to end-of-
treatment and 3-month follow-up could not be calculated 
Ruglass, Hien, Hu, & 
Campbell (2014) 
 Baseline to end-of-
treatment 
Baseline to 12-month 
follow-up 
PTSD symptom severity1 Seeking Safety -44% -59% 
Women’s Health 
Education  
-48% -51% 
Past 30-day stimulant 
use2 
Seeking Safety -79% -66% 
Women’s Health 
Education 
-54% -50% 
1 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
2 Measured using Addiction Severity Index – Lite (ASI-Lite) 
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Table 4 (continued).  
 
McGovern, Lambert-
Harris, Alterman, Xie, & 
Meier (2011) 
 Baseline to 3-month 
follow-up 
Baseline to 6-month 
follow-up 
PTSD symptom severity1 CBT -52% -39%b 
Treatment as usual  -37% -41% 
Drug problem severity2 CBT -37% -47%c 
Treatment as usual  -45% -50% 
Alcohol problem severity3 CBT -72% -56%c 
Treatment as usual  -79% -88% 
Past 90-day drug use4 CBT -55% -65%c 
Treatment as usual  -32% -30% 
1 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
2 Measured using Self-Administered Addiction Severity Index (SA-ASI); higher scores on the drug 
subsection indicate greater drug problem severity 
3 Measured using Self-Administered Addiction Severity Index (SA-ASI); higher scores on the 
alcohol subsection indicate greater drug problem severity 
4 Measured using Time Line Follow-Back (TLFB); objective measurements were also taken to 
validate self-report 
b Used to calculate the average percentage change in PTSD outcomes as a result of CPT for 
PTSD in Appendix 
c Used to calculate the average percentage change in substance use outcomes as a result of 
CPT for PTSD in Appendix  
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Table 4 (continued).  
 
Zlotnick, Johnson, & 
Najavits (2009) 
 Baseline to end-of-
treatment 
Baseline to 6-month 
follow-up 
PTSD symptom severity1 Seeking Safety -18% -34%b 
Treatment as usual -28% -27% 
Drug problem severity2 Seeking Safety Not given -30%c 
Treatment as usual Not given -33% 
Alcohol problem severity3 Seeking Safety Not given -57%c 
Treatment as usual Not given -31% 
1 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores worse PTSD 
outcomes 
2 Measured using Addiction Severity Index (ASI); higher scores on the drug subsection indicate 
greater drug problem severity 
3 Measured using Addiction Severity Index (ASI); higher scores on the alcohol subsection indicate 
greater drug problem severity 
b Used to calculate the average percentage change in PTSD outcomes as a result of CPT for 
PTSD in Appendix  
c Used to calculate the average percentage change in substance use outcomes as a result of 
CPT for PTSD in Appendix 
aThis table shows the percentage changes in PTSD and SUD outcomes from baseline to the end 
of treatment and last point of follow-up in studies (described in Table 3) using CPT to treat PTSD 
in individuals with concurrent PTSD and SUD. PTSD = posttraumatic stress disorder; SUD = 
substance use disorder; CPT = cognitive processing therapy; CBT = cognitive behavioral therapy. 
 
 
Psychological Treatment for Concomitant PTSD and SMI 
The studies presented in this section are the key features and findings of three 
randomized controlled trials (RCTs) (Mueser et al., 2015, 2008; Steel et al., 2017) and 
two non-RCTs included for their relevant setting (Mueser et al., 2007) and population 
(Nishith, Mueser, & Morse, 2015). These studies examined the efficacy of psychological 
treatment on PTSD in individuals with PTSD and concurrent SMI. Selection of these 
studies was based on their treatment of vulnerable populations and their ability to be 
carried out in community-based outpatient or inpatient settings serving primarily 
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underserved populations. The studies meeting these criteria were used to determine the 
efficacy of cognitive processing therapy (CPT), prolonged exposure (PE), and EMDR on 
PTSD and SMI outcomes.  
Cognitive processing therapy studies 
Table 5 presents five studies (three RCTs and two non-RCTs) that used CPT to 
treat PTSD in individuals with concurrent PTSD and SMI. Each study is characterized by 
(1) recruitment strategy, (2) participant characteristics, (3) study protocol, and (4) 
treatment conditions. 
 
Table 5. Key Features of Studies Using CPT to Treat PTSD in Individuals With 
Concurrent PTSD and SMIa 
 
Mueser et al. (2007)  
Recruitment 
strategy 
N = 80; not a RCT 
 
Referrals to trauma recovery groups by clinicians at Mental Health Center of 
Greater Manchester (New Hampshire), a community mental health center setting 
Participant 
characteristics  
PTSD and SMI; 79% women; 99% White; most common SMIs: 35% personality 
disorder, 20% major depression, 12% schizophrenia or schizoaffective disorder, 
9% bipolar disorder; not excluded on past or present SUD 
Study protocol 21 weekly group sessions with topics such as: breathing retraining, education, 
cognitive restructuring, coping skills, developing a recovery plan  
Treatment 
conditions  
Individuals participated in trauma recovery groups of 6-8 participants led by two 
co-therapists, in addition to receiving service at the mental health center as usual 
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Table 5 (continued). 
 
Mueser et al. (2008)  
Recruitment 
strategy 
N = 108  
 
Individuals, with case managers, receiving services at 4 publically funded 
community mental health centers in northeastern US 
Participant 
characteristics  
PTSD and SMI; excluded on the presence of a severe SUD; 84% White; 21% 
men 
Study protocol 12-16 sessions over 4-6 months  
Treatment 
conditions  
Group 1: TAU + CPT. Participants continued to receive comprehensive treatment 
for their psychiatric illness at their local community mental health center plus CPT 
for PTSD (e.g., crisis plan review, psychoeducation, cognitive restructuring) 
 
Group 2: TAU. Participants continued to receive comprehensive treatment for 
their psychiatric illness at their local community mental health center (no cognitive 
restructuring or exposure therapy offered)  
Nishith, Mueser, & Morse (2015)  
Recruitment 
strategy 
N = 18; not a RCT 
 
Individuals receiving care at a large behavioral health care center in St. Louis, 
Missouri, which specializes in providing services to people with SMI who are 
underserved  
Participant 
characteristics  
PTSD diagnosis (not necessarily severe); SMI; excluded on participation in 
another trauma-focused treatment (e.g., PE, CPT/cognitive restructuring, related 
treatment protocols that address ways of thinking about trauma and/or provide 
education on how to best cope with it); “predominantly minority persons”; low-
income 
Study protocol 3 weekly sessions 
 
Treatment 
conditions  
Individuals participated in a brief treatment program, a 3-session intervention for 
PTSD that provides education on trauma and PTSD, breathing retraining, and 
strategies for coping with anxiety and arousal; cognitive restructuring was not 
addressed; additionally, participants continued to receive SMI services at the 
behavioral health care center as usual 
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Table 5 (continued).  
 
Mueser et al. (2015)  
Recruitment 
strategy 
N = 201 
 
Individuals receiving mental health services at any of 5 hospital or outpatient 
programs in Northern and Central New Jersey (urban settings) as part of the 
Rutgers University Behavioral Health Care network  
Participant 
characteristics  
PTSD (severe); SMI; “diverse minority ethnic groups”; 56% Black/African 
American; 34% White; 69% women; 18% Hispanic 
Study protocol 12-16 weeks for CBT and 3 sessions for brief CBT 
Treatment 
conditions  
Group 1: CPT. Participants continued to receive their usual psychiatric services 
plus a CPT program containing breathing retraining, education about trauma and 
PTSD, and cognitive restructuring  
 
Group 2: Brief CBT. Participants continued to receive their usual psychiatric 
services plus a brief CBT program containing only breathing retraining and 
education about trauma and PTSD (i.e., no cognitive restructuring) 
Steel et al. (2017)  
Recruitment 
strategy 
N = 61 
 
Individuals receiving services in either of two large National Health Service 
facilities located in South England  
Participant 
characteristics  
PTSD (full or subthreshold); schizophrenia/schizoaffective 
disorder/schizophreniform disorder; 62% men; 72% White 
Study protocol Maximum of 16 sessions over 6 months 
Treatment 
conditions  
Group 1: CPT. Participants continued to receive their usual psychiatric services 
plus a CPT for PTSD protocol conducted at their local community mental health 
center or at their home  
 
Group 2: TAU. Participants continued to receive the usual services available to 
them through their clinical teams 
aThis table shows the key features of five studies examining the effect of CPT on PTSD and 
mental health outcomes in individuals receiving treatment as usual for SMI in a community or 
low-income health care setting. CPT = cognitive processing therapy; PTSD = posttraumatic stress 
disorder; SMI = serious mental illness; RCT = randomized controlled trial; TAU = treatment as 
usual; CBT = cognitive behavioral therapy.  
 
 
Cognitive processing therapy findings 
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Outcomes of interest with respect to all of the studies described in Table 5 
involved PTSD symptom severity and mental health.  
Mueser et al. (2007) examined the efficacy of CPT in the form of trauma recovery 
groups on PTSD in individuals with SMI, such as major depression, 
schizophrenia/schizoaffective disorder, and/or bipolar disorder. Outcomes of interest 
were measured at baseline, end-of-treatment, and 3 months follow-up for PTSD symptom 
severity and depression (Mueser et al., 2007). The researchers found that the 
improvements in PTSD symptom severity were significant from baseline to the end of 
treatment (p < 0.001) and from baseline to the 3-month follow-up (p < 0.001) (Mueser et 
al., 2007). Also, there were significant decreases in depression from baseline to the end of 
treatment (p < 0.05) and from baseline to the 3-month follow-up (p < 0.01) (Mueser et 
al., 2007).  
In another study, Mueser et al. (2008) investigated the efficacy of a different CPT 
protocol for PTSD in individuals with SMI. Participants in this randomized controlled 
trial (RCT) were assigned to receive CPT for PTSD in addition to their mental health 
treatment (Group 1) or treatment as usual for mental illness alone (Group 2) (Mueser et 
al., 2008). Outcomes of interest were measured at baseline, end-of-treatment, 3 months 
follow-up, and 6 months follow-up and consisted of PTSD symptoms, depression, and 
strength of patient-case manager therapeutic alliance in which the case manager was a 
member of the patient’s mental health team and not affiliated with the study (Mueser et 
al., 2008). The researchers found that Group 1 individuals fared significantly better than 
Group 2 individuals with respect to PTSD symptom severity from baseline to the last 
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assessment (p = 0.005) (Mueser et al., 2008). Individuals in Group 1 also improved 
significantly more than individual in Group 2 with respect to depression (Mueser et al., 
2008). Scores for depression decreased in both groups, but the drop from baseline to 6-
month follow-up was significantly greater among individuals receiving CPT than 
individuals receiving treatment as usual for mental illness alone (p < 0.001) (Mueser et 
al., 2008). With respect to the therapeutic alliance between patients and their respective 
case managers, the relationships involving individuals from Group 1 strengthened 
significantly more than the alliances involving individuals from Group 2 (p = 0.009) 
(Mueser et al., 2008). 
Nishith and coworkers studied the effect of a brief CPT protocol (3 sessions; no 
cognitive restructuring) for PTSD treatment on PTSD and mental health outcomes 
(Nishith et al., 2015). Outcomes of interest were measured at baseline, end-of-treatment, 
and 3 months follow-up for PTSD symptom severity (measured with clinician-
administered and self-administered tools) and depression (Nishith et al., 2015). The 
researchers found that study participants improved significantly on all three outcomes 
from baseline to the end of treatment (clinician-administered PTSD symptom severity: p 
< 0.01; self-administered PTSD symptom severity: p < 0.01; depression: p < 0.05) 
(Nishith et al., 2015). Participants’ scores on all three outcomes at the 3-month follow-up 
were not significantly different from those at the end of treatment, implying that the 
treatment gains were maintained (Nishith et al., 2015).  
A study by Mueser et al. (2015) also examined the effect of CPT for PTSD in 
individuals with SMI. Participants in this RCT were assigned to receive a CPT protocol 
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that included cognitive restructuring (Group 1) or a CPT protocol that did not (brief CPT; 
Group 2) (Mueser et al., 2015). Outcomes of interest were measured at baseline, end-of-
treatment, 6 months follow-up, and 12 months follow-up for PTSD symptom severity, 
depression, quality of life, psychosocial functioning, and overall functioning (Mueser et 
al., 2015). With respect to PTSD symptom severity, the researchers found that individuals 
in Group 1 improved significantly more than individuals in Group 2 (p = 0.01) (Mueser 
et al., 2015). Furthermore, individuals in both groups did significantly better from the end 
of treatment to the 6- and 12-month follow-ups (p = 0.03) (Mueser et al., 2015). With 
respect to depression, there was no significant group effect, but the researchers found a 
significant time effect (Mueser et al., 2015). Individuals in both groups became 
significantly less depressed from the end of treatment to the 6-month follow-up and to the 
12-month follow-up (p = 0.04) (Mueser et al., 2015). For quality of life ratings, which 
tended to increase similarly from baseline to follow-up assessments in both groups, there 
was no significant group effect, and there was also no significant time effect from the end 
of treatment to follow-up assessments at 6 and 12 months (Mueser et al., 2015). 
However, a significant group effect on psychosocial functioning was found with 
individuals in Group 1 performing better than individuals in Group 2 (p = 0.05) (Mueser 
et al., 2015). In addition, there was a significant group x time interaction with respect to 
psychosocial functioning in which individuals receiving CPT were significantly better 
across time than individuals receiving only brief CBT (p < 0.02) (Mueser et al., 2015). 
Finally, the researchers showed a significant treatment effect on overall functioning with 
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individuals in Group 1 faring significantly better than individuals in Group 2 (p = 0.03) 
(Mueser et al., 2015).  
Steel et al. (2017) examined the efficacy of a CPT protocol for PTSD in 
individuals with schizophrenia. Participants in this RCT were assigned to receive CPT in 
addition to their treatment as usual (Group 1) or to keep receiving treatment as usual 
alone (Group 2) (Steel et al., 2017). Outcomes of interest were measured at baseline, end-
of-treatment, and 6-month follow-up and consisted of PTSD symptom severity, 
depression, quality of life, and overall functioning (Steel et al., 2017). The researchers 
found no significant treatment effect on PTSD symptom severity; PTSD symptom 
severity improved in both groups with no significant difference between groups (Steel et 
al., 2017). Within each group, PTSD symptom severity decreased significantly from 
baseline to the 6-month follow-up (i.e., over a period of 12 months) (Steel et al., 2017). 
There were also no significant between-group differences with respect to depression, 
quality of life, and overall functioning (Steel et al., 2017). Depression decreased in both 
groups from baseline to the 6-month follow-up, but neither within-group drop was 
significant (Steel et al., 2017). Quality of life increased slightly in Group 1 and dropped 
in Group 2, while overall functioning increased in both groups from baseline to the 6-
month follow-up (Steel et al., 2017). Thus, Steel et al. (2017) concluded that the addition 
of CPT for PTSD in individuals receiving treatment for schizophrenia did not improve 
their PTSD or mental health outcomes any more than treatment for SMI alone.  
Table 6 displays the percentage changes in each of the aforementioned PTSD- and 
SMI-specific variables over the course of each of the five studies. The impact of 
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treatment assignment on these variables can provide a better idea of the effect of CPT on 
PTSD and mental health outcomes in individuals with PTSD and SMI. In most cases, 
depending on the data provided, a percentage change was calculated from baseline to the 
end of treatment as well as from baseline to the last point of follow-up. 
 
Table 6. Percentage Changes in PTSD and SMI Outcomes in Studies Using CPTa  
 
Mueser et al. (2007)  Baseline to end-of-
treatment 
Baseline to 3-month 
follow-up 
PTSD symptom severity1 -20% -20%b 
Depression2 -25% -23%c 
1 Assessed with PTSD Checklist (PCL) by clinician at baseline and subsequently by self-
administration  
2 Assessed with Beck Depression Inventory (BDI)  
b Used to calculate the average percentage change in PTSD outcomes as a result of CPT for 
PTSD in Appendix 
c Used to calculate the average percentage change in mental health outcomes as a result of CPT 
for PTSD in Appendix 
Mueser et al. (2008)  Baseline to end-of-
treatment 
Baseline to 6-month 
follow-up 
PTSD symptom 
severity1 
CPT -25% -23%b 
TAU -11% -7% 
Depression2 CPT -30% -21%c 
TAU -13% -1% 
Therapeutic alliance3 CPT +2% +7%c 
TAU -5% -2% 
1 Assessed using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
2 Assessed with Beck Depression Inventory II (BDI-II)  
3 Assessed using Working Alliance Inventory (WAI); higher scores indicate a stronger case 
manager-patient alliance  
b Used to calculate the average percentage change in PTSD outcomes as a result of CPT for 
PTSD in Appendix 
c Used to calculate the average percentage change in mental health outcomes as a result of CPT 
for PTSD in Appendix 
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Table 6 (continued).  
 
Nishith, Mueser, & 
Morse (2015) 
 Baseline to end-of-
treatment 
Baseline to 3-month 
follow-up 
PTSD symptom severity1  -40% -49%d 
PTSD symptom severity2 -68% -78%d 
Depression3  -52% -62%e 
1 Measured using self-administered PTSD Checklist (PCL); higher scores indicate greater 
frequency and intensity of PTSD symptoms  
2 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
3 Assessed with Beck Depression Inventory II (BDI-II)  
d Used to calculate the average percentage change in PTSD outcomes as a result of brief CPT 
for PTSD in Appendix 
e Used to calculate the average percentage change in mental health outcomes as a result of brief 
CPT for PTSD in Appendix 
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Table 6 (continued).  
 
Mueser et al. (2015)  Baseline to end-of-
treatment 
Baseline to 12-month 
follow-up 
PTSD symptom 
severity1 
CPT -26% -30%b 
Brief CPT -20% -23%d 
Depression2 CPT -19% -23%c 
Brief CPT -13% -25%e 
Quality of life3 CPT +30% +35%c 
Brief CPT +13% +16%e 
Psychosocial 
functioning4 
CPT -31% -34%c 
Brief CPT -19% -36%e 
Overall functioning5 CPT +16% +19%c 
Brief CPT +15% +16%e 
1 Assessed using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
2 Assessed with Beck Depression Inventory II (BDI-II)  
3 Assessed using Quality of Life Interview (QoLI); higher scores indicate greater subjective quality 
of life across multiple domains 
4 Assessed using Clinician-Administered PTSD Scale (CAPS); higher scores on the psychosocial 
functioning subsection indicate worse social functioning 
5 Assessed using Global Assessment of Functioning (GAF) scale 
b Used to calculate the average percentage change in PTSD outcomes as a result of CPT for 
PTSD in Appendix 
c Used to calculate the average percentage change in mental health outcomes as a result of CPT 
for PTSD in Appendix 
d Used to calculate the average percentage change in PTSD outcomes as a result of brief CPT 
for PTSD in Appendix 
e Used to calculate the average percentage change in mental health outcomes as a result of brief 
CPT for PTSD in Appendix 
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Table 6 (continued).  
 
Steel et al. (2017)  Baseline to end-of-
treatment 
Baseline to 6-month 
follow-up 
PTSD symptom 
severity1 
CPT -16% -31%b 
TAU -31% -44% 
Depression2 CPT -20% -28%c 
TAU -7% -19% 
Quality of life3 CPT -8% +2%c 
TAU -2% -2% 
Overall functioning4 CPT +10% +10%c 
TAU +7% +4% 
1 Assessed using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
2 Assessed with Beck Depression Inventory II (BDI-II)  
3 Assessed with Quality of Life Scale (QoLS)  
4 Assessed using Global Assessment of Functioning (GAF) scale 
b Used to calculate the average percentage change in PTSD outcomes as a result of CPT for 
PTSD in Appendix 
c Used to calculate the average percentage change in mental health outcomes as a result of CPT 
for PTSD in Appendix 
aThis table shows the percentage changes in PTSD and SMI outcomes from baseline to the end of 
treatment and last point of follow-up in studies (described in Table 5) using CPT to treat PTSD in 
individuals with concurrent PTSD and SMI. PTSD = posttraumatic stress disorder; SMI = serious 
mental illness; CPT = cognitive processing therapy; TAU = treatment as usual. 
 
 
Prolonged exposure studies 
 
Table 7 presents three studies (two primary analyses of RCTs and one secondary 
analysis of a RCT) that examined the impact of PE on PTSD and mental health outcomes 
in individuals with concurrent PTSD and SMI. Each study is characterized by (1) 
recruitment strategy, (2) participant characteristics, (3) study protocol, and (4) treatment 
conditions. 
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Table 7. Key Features of Studies Using PE to Treat PTSD in Individuals With 
Concurrent PTSD and SMIa 
 
de Bont, van Minnen, & de Jongh (2013) 
Recruitment 
strategy 
N = 10  
 
Individuals referred by their therapists from a Dutch mental health outpatient 
center  
Participant 
characteristics  
PTSD; psychotic episode experienced in past 3 years with symptoms remaining 
and current treatment being sought; no exclusion for SUD  
Study protocol 12 90-minute sessions  
Treatment 
conditions  
Group 1: PE. Participants continued to receive treatment as usual for their 
psychosis plus PE therapy 
 
Group 2: EMDR. Participants continued to receive treatment as usual for their 
psychosis plus EMDR 
van den Berg et al. (2015) 
Recruitment 
strategy 
N = 155 
 
13 comparable Dutch outpatient services for individuals with SMI  
Participant 
characteristics  
PTSD; lifetime diagnosis of a psychotic disorder or mood disorder; not excluded 
on presence of current psychotic symptoms 
Study protocol 8 weekly 90-minute sessions within 10 weeks 
Treatment 
conditions  
Group 1: PE. Participants received treatment as usual (non-trauma-focused 
therapies) for psychosis delivered by multidisciplinary teams consisting of 
psychologists, caseworkers, nurses, and psychiatrists plus PE therapy 
 
Group 2: EMDR. Participants received treatment as usual (non-trauma-focused 
therapies) for psychosis delivered by multidisciplinary teams consisting of 
psychologists, caseworkers, nurses, and psychiatrists plus EMDR 
 
Group 3: Control. Participants received treatment as usual (non-trauma-focused 
therapies) for psychosis delivered by multidisciplinary teams consisting of 
psychologists, caseworkers, nurses, and psychiatrists; after the 6-month follow-
up they discussed potential PTSD treatment options with a study clinician  
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Table 7 (continued).  
 
de Bont et al. (2016)   
Recruitment 
strategy 
N = 155; the same sample studied by van den Berg et al. (2015)  
 
13 comparable Dutch outpatient services for individuals with SMI  
Participant 
characteristics  
PTSD; lifetime diagnosis of a psychotic disorder or mood disorder; not excluded 
on presence of current psychotic symptoms 
Study protocol 8 weekly 90-minute sessions within 10 weeks 
Treatment 
conditions  
Group 1: PE. Participants received treatment as usual (non-trauma-focused 
therapies) for psychosis delivered by multidisciplinary teams consisting of 
psychologists, caseworkers, nurses, and psychiatrists plus PE therapy 
 
Group 2: EMDR. Participants received treatment as usual (non-trauma-focused 
therapies) for psychosis delivered by multidisciplinary teams consisting of 
psychologists, caseworkers, nurses, and psychiatrists plus EMDR 
 
Group 3: Control. Participants received treatment as usual (non-trauma-focused 
therapies) for psychosis delivered by multidisciplinary teams consisting of 
psychologists, caseworkers, nurses, and psychiatrists; after the 6-month follow-
up they discussed potential PTSD treatment options with a study clinician 
aThis table shows the key features of 3 studies (two primary analyses and one secondary analysis 
of RCTs) examining the effect of PE on PTSD and mental health outcomes in individuals 
receiving treatment as usual for SMI in a community or low-income health care setting. 
PE = prolonged exposure; PTSD = posttraumatic stress disorder; SMI = serious mental illness;  
SUD = substance use disorder; EMDR = eye movement desensitization and reprocessing.  
 
 
Prolonged exposure findings 
Outcomes of interest with respect to all of the studies described in Table 7 involve 
PTSD symptom severity and mental health.  
De Bont et al. (2013) examined the impact of evidence-based, trauma-focused 
treatment for PTSD, in the form of PE or EMDR, on PTSD and SMI in individuals 
comorbid for both. Outcomes of interest were measured at baseline, end-of-treatment, 
and 3 months follow-up for PTSD symptom severity, general psychopathology and 
distress, psychosocial functioning, and psychotic symptom severity (de Bont et al., 2013). 
Although five individuals were randomly assigned to Group 1 to receive PE and five 
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individuals were randomly assigned to Group 2 to receive EMDR, the researchers 
presented outcomes for the entire sample as a whole (de Bont et al., 2013). PTSD 
symptom severity (measured with PSS-SR) decreased significantly from baseline to the 
end of treatment (p < 0.001) and remained significantly lower in the follow-up phase (p < 
0.001) (de Bont et al., 2013). With respect to PTSD symptom severity measured using 
CAPS, individuals fared significantly better at follow-up compared with baseline (p = 
0.012) (de Bont et al., 2013). At the end of treatment, CAPS scores were almost 
significantly better than they were at baseline (p = 0.05) (de Bont et al., 2013). With 
respect to general psychopathology and distress, scores were significantly lower at the 
end of treatment (p = 0.028) and at the 3-month follow-up (p = 0.018) than they were at 
baseline (de Bont et al., 2013). Psychosocial functioning was not significantly different 
among individuals of the study at the end of treatment or the 3-month follow-up, 
compared with baseline (de Bont et al., 2013). Similarly, psychotic symptom severity did 
not change significantly with respect to either auditory hallucinations or delusions among 
study individuals from baseline to the end of treatment or from baseline to the 3-month 
follow-up (de Bont et al., 2013).  
A study by van den Berg et al. (2015) also examined the impact of PE (Group 1) 
and EMDR (Group 2) on PTSD and SMI. Outcomes of interest measured at baseline, 
end-of-treatment, and the 6-month follow-up consisted of PTSD symptom severity 
evaluated by a self-administered tool and the clinician-administered PTSD scale (CAPS) 
(van den Berg et al., 2015). The researchers found that individuals in Group 1 and in 
Group 2 scored significantly lower on the CAPS at the end of treatment (Group 1: p < 
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0.001; Group 2: p = 0.001) and at the 6-month follow-up (Group 1: p = 0.002; Group 2: p 
= 0.009) compared with individuals in the control (van den Berg et al., 2015). In addition, 
there were no significant differences between individuals receiving PE and those 
receiving EMDR at any time point (van den Berg et al., 2015). Similarly, the scores for 
self-reported PTSD symptom severity were significantly lower for individuals in Group 1 
and in Group 2 at the end of treatment (Group 1: p < 0.001; Group 2: p < 0.001) and at 
the 6-month follow-up (Group 1: p = 0.001; Group 2: p = 0.001) compared with 
individuals in the control (van den Berg et al., 2015). Again, there were no significant 
differences between individuals receiving PE and those receiving EMDR at any time 
point (van den Berg et al., 2015). However, this study found that individuals who 
received PE therapy were more likely than individuals in the control to experience full 
PTSD remission both at the end of treatment (p = 0.01) and at the 6-month follow-up (p = 
0.01) (van den Berg et al., 2015). Individuals who received EMDR were not more likely 
than those in the control to achieve the same loss of PTSD diagnosis (van den Berg et al., 
2015). Also, there were no significant differences among individuals in Group 1 or 
individuals in Group 2 on prevalence of full PTSD remission at any time point (van den 
Berg et al., 2015).  
De Bont and colleagues (2016) studied the same population examined on PTSD 
symptom severity by van den Berg et al. (2015). Outcomes of interest measured at 
baseline, end-of-treatment, and the 6-month follow-up were depression, psychosocial 
functioning, paranoid thoughts, and psychotic symptom severity (de Bont et al., 2016). 
Individuals receiving PE were significantly less depressed than individuals in the control 
 54 
and individuals receiving EMDR at the end of treatment (p < 0.05), 6 months follow-up 
(p = 0.026), and over time (p = 0.036) (de Bont et al., 2016). Group assignment did not 
impact individuals’ scores on psychosocial functioning at any of the three time points (de 
Bont et al., 2016). Individuals who received either PE or EMDR displayed significantly 
less paranoid thoughts compared with individuals in the control group at the end of 
treatment (p < 0.05 for both groups) (de Bont et al., 2016). At the 6-month follow-up, 
only those who received PE had significantly less paranoid thoughts than those in the 
control (p < 0.05) (de Bont et al., 2016). Group assignment also did not impact 
individuals’ psychotic symptom severity with respect to auditory hallucinations at any of 
the three time points (de Bont et al., 2016). 
Table 8 displays the percentage changes in each of the aforementioned PTSD- and 
SMI-specific variables over the course of each of the three studies. The impact of 
treatment assignment on these variables can provide a better idea of the effect of PE and 
EMDR on PTSD and mental health outcomes in individuals with PTSD and SMI. In most 
cases, depending on the data provided, a percentage change was calculated from baseline 
to the end of treatment as well as from baseline to the last point of follow-up.  
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Table 8. Percentage Changes in PTSD and SMI Outcomes in Studies Using PEa 
 
de Bont, van Minnen, & de 
Jongh (2013)* 
Baseline to end-of-
treatment 
Baseline to 3-month follow-up 
PTSD symptom severity1  -51% -56% 
PTSD symptom severity2 -32% -47% 
General psychopathology and 
distress3 
-14% -16% 
Psychosocial functioning4 +3% +1% 
Psychotic symptom severity - 
auditory hallucinations5 
-26% -11% 
Psychotic symptom severity – 
delusions6  
-69% -69% 
* While five individuals were randomly assigned to receive PE and 5 individuals were randomly 
assigned to receive EMDR, the authors presented outcomes for the entire sample as a whole 
1 Measured using Post Traumatic Stress Disorder Symptom Scale – Self Report (PSS-SR); 
higher scores indicate greater frequency and intensity of PTSD symptoms  
2 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
3 Measured using Outcome Questionnaire (OQ-45.2); higher scores indicate greater distress 
4 Measured using Social Functioning Scale (SFS); higher scores represent greater social 
functioning 
5 Measured using auditory hallucination subscale of clinician-administered Psychotic Symptom 
Rating Scale (PSYRATS) 
6 Measured using delusion subscale of Psychotic Symptom Rating Scale (PSYRATS) 
van den Berg et al. 
(2015) 
 Baseline to end-of-
treatment 
Baseline to 6-month follow-up 
PTSD symptom 
severity1  
PE -44% -42%b 
EMDR -47% -47%d 
Control -7% -13% 
PTSD symptom 
severity2 
PE -46% -47%b 
EMDR -44% -46%d 
Control -17% -24% 
1 Measured using Post Traumatic Stress Disorder Symptom Scale – Self Report (PSS-SR); 
higher scores indicate greater frequency and intensity of PTSD symptoms  
2 Measured using Clinician-Administered PTSD Scale (CAPS); higher scores indicate worse 
PTSD outcomes 
b Used to calculate the average percentage change in PTSD outcomes as a result of PE for 
PTSD in Appendix 
d Used to calculate the average percentage change in PTSD outcomes as a result of EMDR for 
PTSD in Appendix 
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Table 8 (continued).  
 
de Bont et al. (2016)  Baseline to end-of-
treatment 
Baseline to 6-month follow-up 
Depression1 PE -40% -42%c 
EMDR -21% -19%e 
Control -10% -18% 
Psychosocial 
functioning2 
PE +3% +3%c 
EMDR +5% +2%e 
Control -2% -5% 
Paranoid thoughts 
(think: quality of life)3 
PE -24% -27%c 
EMDR -18% -15%e 
Control -1% -7% 
Psychotic symptom 
severity - auditory 
hallucinations4 
PE -13% +4%c 
EMDR -31% -34%e 
Control +5% -27% 
1 Assessed with Beck Depression Inventory II (BDI-II)  
2 Assessed with Personal and Social Performance (PSP) Scale 
3 Assessed with Green Paranoid Thoughts Scale (GPTS)  
4 Assessed with auditory hallucination subscale of clinician-administered Psychotic Symptom 
Rating Scale (PSYRATS) 
c Used to calculate the average percentage change in mental health outcomes as a result of PE 
for PTSD in Appendix 
e Used to calculate the average percentage change in mental health outcomes as a result of 
EMDR for PTSD in Appendix 
aThis table shows the percentage changes in PTSD and SMI outcomes from baseline to the end of 
treatment and last point of follow-up in studies (described in Table 7) using PE to treat PTSD in 
individuals with concurrent PTSD and SMI. PTSD = posttraumatic stress disorder; SMI = serious 
mental illness; PE = prolonged exposure; EMDR = eye movement desensitization and 
reprocessing.  
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DISCUSSION 
 
PTSD is often comorbid with SUD (Dore et al., 2012) or SMI (Grubaugh et al., 
2011). Although CBT, including trauma-focused PE and trauma-focused CPT, is the gold 
standard treatment for PTSD (Friedman, 2015b), the use of trauma-focused psychological 
treatment options is often questioned in vulnerable populations for fear that PTSD and/or 
SUD or SMI symptoms will worsen (Friedman, 2015b; Schnyder & Cloitre, 2015). 
In the studies that administered PE to individuals with PTSD and SUD (Tables 1 
and 2), the PE protocol was administered alongside SUD treatment (Coffey et al., 2016, 
2006) or integrated with SUD treatment such that a single protocol had sessions of PTSD 
and SUD treatment (i.e., each session had components of safety/trauma and substance 
use) (Mills et al., 2012; Ruglass et al., 2017; Sannibale et al., 2013). On average, when 
PE was administered alongside SUD treatment, PTSD symptom severity improved by 
66% (n = 2; see Appendix for calculation) from baseline to the last point of follow-up 
(Coffey et al., 2016, 2006). With respect to substance use outcomes (alcohol craving, 
alcohol use, and drug use), those who received PE alongside a separate substance use 
treatment program improved approximately 77% (n = 4; see Appendix for calculation) 
(Coffey et al., 2016, 2006).  
When PE was integrated with SUD treatment such that PTSD and substance 
abuse treatment were provided in a single protocol, PTSD symptom severity improved by 
42% (n = 3; see Appendix for calculation) and substance use outcomes (alcohol use, 
drinks per drinking day, number of substance use dependence criteria met, substance use 
abstinence, and drug use) improved by approximately 71% (n = 5; see Appendix for 
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calculation) (Mills et al., 2012; Ruglass et al., 2017; Sannibale et al., 2013). Individuals 
who received the COPE protocol (Mills et al., 2012; Ruglass et al., 2017) improved about 
the same on PTSD symptom severity as those who received a non-COPE exposure-based 
protocol that integrated PTSD and AUD treatment (Sannibale et al., 2013). However, 
those receiving non-COPE exposure therapy improved almost three times more on 
substance use outcomes than those receiving COPE, possibly because Sannibale et al. 
(2013) excluded individuals for severe substance use disorders.  
In the studies that administered non-exposure-based CBT, specifically cognitive 
processing therapy (CPT), to individuals with PTSD and SUD (Tables 3 and 4), CPT was 
integrated with SUD treatment through either the Seeking Safety protocol (Hien et al., 
2004, 2009; Najavits et al., 2006; Zlotnick et al., 2009) or a non-Seeking Safety CPT 
protocol that integrated PTSD and SUD treatment (McGovern et al., 2011). On average, 
the improvement in PTSD symptom severity was 38% (n = 5; see Appendix for 
calculation) for individuals who received integrated CPT (Hien et al., 2004, 2009; 
McGovern et al., 2011; Zlotnick et al., 2009). With respect to substance use outcomes 
(e.g., drug or alcohol use, drug problem severity, and alcohol problem severity), the 
average percentage improvement was 46% (n = 6; see Appendix for calculation) (Hien et 
al., 2009; McGovern et al., 2011; Zlotnick et al., 2009). 
Individuals who received the SS protocol in four studies (Hien et al., 2004, 2009; 
Najavits et al., 2006; Zlotnick et al., 2009) fared similarly with respect to PTSD symptom 
severity as those who received the non-SS integrated CPT protocol for PTSD and SUD 
(McGovern et al., 2011). However, those who received the non-SS integrated CPT 
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protocol improved slightly more on substance use outcomes, with a 56% (n = 3; see 
Appendix for calculation) improvement versus a 35% (n = 3; see Appendix for 
calculation) improvement found in the studies using SS. It is possible, however, that 
those in the non-SS study improved more on substance use outcomes because they 
received methadone maintenance, a very effective pharmacological treatment for SUD, 
for their treatment as usual. 
PE that is administered alongside SUD treatment (Coffey et al., 2016, 2006) has a 
greater impact on PTSD symptom severity and substance use outcomes than either (1) PE 
integrated with SUD treatment (Mills et al., 2012; Ruglass et al., 2017; Sannibale et al., 
2013) or (2) CPT integrated with SUD treatment (Hien et al., 2004, 2009; McGovern et 
al., 2011; Najavits et al., 2006; Zlotnick et al., 2009). One possible reason for this is that 
keeping PTSD treatment and SUD treatment separate allows for participants to continue 
with PTSD treatment if SUD treatment is no longer desirable, or vice versa (Coffey et al., 
2016). Although PE that is integrated with SUD treatment has a similar effect on PTSD 
symptoms as CPT that is integrated with SUD treatment, individuals who receive PE do 
better on substance use outcomes than individuals who receive CPT. 
Among individuals with PTSD and concurrent SMI (Tables 5 and 6), CPT 
improved PTSD symptom severity by an average of 26% (n = 4; see Appendix for 
calculation) (Mueser et al., 2007, 2015, 2008; Steel et al., 2017). With respect to mental 
health outcomes (depression, therapeutic alliance, quality of life, psychosocial 
functioning, and overall functioning), the average improvement was 20% (n = 10; see 
Appendix for calculation) (Mueser et al., 2007, 2015, 2008; Steel et al., 2017). Although 
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the CPT for SMI protocols ranged from 12 to 21 sessions, when individuals were given 3 
sessions of CPT, the average PTSD symptom severity improvement was 50% (n = 3; see 
Appendix for calculation) and the average improvement in mental health outcomes 
(depression, quality of life, psychosocial functioning, and overall functioning) was 31% 
(n = 5; see Appendix for calculation) (Mueser et al., 2015; Nishith et al., 2015).  
Mueser et al. (2015) showed that individuals receiving a full CPT for PTSD 
protocol improved significantly more than those receiving 3 sessions (i.e., no cognitive 
restructuring); however, individuals in both groups improved significantly from the end 
of treatment to the 6- and 12-month follow-ups. It is possible that percentage 
improvements in PTSD symptom severity and mental health outcomes in individuals 
receiving brief CPT versus full CPT for PTSD are associated with fewer sessions leading 
to greater attendance. Also, it is possible that the breathing retraining component of CPT 
for PTSD protocols has the greatest impact on PTSD symptoms (Mueser et al., 2015). In 
this case, individuals receiving brief CPT are not at a disadvantage because brief CBT 
includes breathing retraining and all the components of a full CPT for PTSD protocol 
except for cognitive restructuring.  
The efficacy of prolonged exposure therapy in individuals with PTSD and SMI 
was compared with the efficacy of EMDR in two different populations (Tables 7 and 8). 
Only in one study population, however, were PTSD and mental health outcomes stratified 
by treatment type. Thus, based on information from a single study population, PE 
improved PTSD symptom severity by an average of 45% (n = 2; see Appendix for 
calculation) (van den Berg et al., 2015) and mental health outcomes (depression, 
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psychosocial functioning, paranoid thoughts, and auditory hallucinations) by an average 
of 17% (n = 4; see Appendix for calculation) (de Bont et al., 2016). In the same study 
population, EMDR improved PTSD symptoms by an average of 47% (n = 2; see 
Appendix for calculation) (van den Berg et al., 2015) and mental health outcomes by an 
average of 18% (n = 4; see Appendix for calculation) (de Bont et al., 2016). 
In both study populations, it was found that PE and EMDR were effective at 
improving PTSD symptom severity in individuals with comorbid PTSD and SMI, 
mitigating the common fear that trauma-focused treatments are too burdensome for 
individuals with PTSD and SMI (van den Berg et al., 2015; de Bont et al., 2013). With 
respect to mental health outcomes, however, it was found that the two treatments differed 
significantly only in their effect on depression, which improved significantly more among 
individuals receiving PE compared with individuals receiving EMDR (van den Berg et 
al., 2015; de Bont et al., 2016). Possible explanations for this result include (1) a greater 
emphasis on being exposed to detailed accounts of one’s traumatic events in PE versus 
EMDR and (2) the ability to process the memory and dispel false cognitions in PE but not 
in EMDR (van den Berg et al., 2015; de Bont et al., 2016). 
Despite the vulnerable nature of study populations with PTSD and concurrent 
SUD or SMI, no adverse events were reported in any of the aforementioned RCTs and 
non-RCTs. In all but one study by McGovern et al. (2011), retention did not differ 
significantly between those groups receiving psychological treatment for PTSD and those 
who did not, indicating that trauma-focused psychological interventions for PTSD can be 
acceptable. Systematic reviews have looked at the impact of psychological treatment 
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options on PTSD in individuals with PTSD and SUD (Roberts, Roberts, Jones, & Bisson, 
2016) and individuals with PTSD and SMI (Sin, Spain, Furuta, Murrells, & Norman, 
2017). This thesis is unique in its focus on the results of RCTs, non-combat PTSD, and 
TAU administered to underserved populations in community or low-income health care 
settings. Of the ten aforementioned study populations with PTSD and SUD, only three 
studies (Coffey et al., 2006; Hien et al., 2004; McGovern et al., 2011) allowed for the 
possible inclusion of individuals with SMI as well. Of the seven aforementioned study 
populations with PTSD and SMI, two studies excluded individuals with substance 
dependence (Mueser et al., 2015, 2008). In the future, research should be done on more 
inclusive populations that reflect the true nature of many vulnerable populations with 
non-combat-related PTSD.  
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CONCLUSION 
 
Treating PTSD in vulnerable populations is a difficult task. Among individuals 
with concomitant PTSD and SUD or concomitant PTSD and SMI, psychological 
treatment options have been studied to varying degrees. PE administered alongside SUD 
treatment has the greatest positive effect on PTSD outcomes and SUD outcomes in 
individuals with dual PTSD and SUD. However, if researchers are choosing between 
implementation of a protocol that integrates PE for PTSD and RPT for SUD (e.g., COPE) 
or a protocol that integrates CPT for PTSD and RPT for SUD (e.g., SS), it is worth 
considering an important factor. Individuals receiving integrated PE tend to do better on 
substance use outcomes than individuals receiving integrated CPT, whereas PTSD 
outcomes are similar for both forms of treatment.  
Compared with concomitant PTSD and SUD, there are fewer studies examining 
the effects of various psychological treatment options on individuals with concomitant 
PTSD and SMI. In the RCTs that have been published, it is preliminarily apparent that 
PE and EMDR have a better impact on PTSD outcomes than non-exposure-based CBT 
(e.g., CPT) from baseline to the last point of follow-up. However, the three forms of 
psychological treatment (PE, EMDR, and CPT) appear to have similar effects on mental 
health outcomes. The choice between implementation of a PE protocol or an EMDR 
protocol must therefore consider the study population of interest among all other factors, 
as individuals receiving PE tend to improve significantly more on depression than 
individuals receiving EMDR.  
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More studies of larger size and randomized controlled nature are necessary to 
examine the effect of various psychological treatment options on populations of 
individuals with PTSD and concomitant SUD or SMI. Although a common PTSD 
outcome is PTSD symptom severity as measured by CAPS, more standard measures for 
SUD and SMI outcomes are needed. As is apparent from the lack of adverse events, these 
trials can and should be as inclusive as possible in recognition of the many comorbidities 
facing individuals with PTSD. 
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APPENDIX 
Table 9. Source Percentage Changes for Calculation of Average Improvementsa  
 
PTSD and SUD studies (Tables 2 and 4) 
TREATMENT 
CONDITIONS 
OUTCOMES 
PTSD outcomes Substance use outcomes 
PE alongside 
TAU 
65%1 and 66%2 improvements 87%1, 33%2, 105%2, and 81%2 
improvements 
Average (n = 2): 66% 
improvement 
Average (n = 4): 77% improvement 
PE integrated 
with SUD TAU 
36%3, 42%4, and 49%5 
improvements 
175%3, 48%3, 57%4, 18%4, and 56%5 
improvements 
Average (n = 3): 42% 
improvement 
Average (n = 5): 71% improvement 
CPT  24%6, 34%7, 61%7, 39%8, 34%9 
improvements 
18%7, 47%8, 56%8, 65%8, 30%9, and 
57%9 improvements 
Average (n = 5): 38% 
improvement 
Average (n = 6): 46% improvement 
SS 34%7, 61%7, and 34%9 
improvements 
18%7, 30%9, and 57%9 improvements 
Average (n = 3): 43% 
improvement 
Average (n = 3): 35% improvement 
Non-SS CPT 39%8 improvement 47%8, 56%8, and 65%8 improvements 
Average (n = 1): 39% 
improvement 
Average (n = 3): 56% improvement 
1 Coffey et al. (2006) 
2 Coffey et al. (2016) 
3 Sannibale et al. (2013) 
4 Mills et al. (2012) 
5 Ruglass et al. (2017) 
6 Hien et al. (2004)  
7 Hien et al. (2009) 
8 McGovern et al. (2011) 
9 Zlotnick et al. (2009) 
PTSD and SMI (Tables 6 and 8) 
TREATMENT 
CONDITIONS 
OUTCOMES 
PTSD outcomes Mental health outcomes 
CPT 20%1, 23%2, 30%4, and 31%5 
improvements 
23%1,
 21%2, 7%2, 23%4, 35%4, 34%4, 
19%4, 28%5, 2%5, and 10%5 
improvements 
Average (n = 4): 26% 
improvement 
Average (n = 10): 20% 
improvement 
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Brief CPT 49%3, 78%3, and 23%4 
improvements 
62%3, 25%4, 16%4, 36%4, and 16%4 
improvements 
Average (n = 3): 50% Average (n = 5): 31% 
PE 42%6 and 47%6 improvements 42%7, 27%7, and 3%7 improvements; 
4%7 worsening 
Average (n = 2): 45% 
improvement 
Average (n = 4): 17% improvement 
EMDR 47%6 and 46%6 improvements 19%7, 2%7, 15%7, and 34%7 
improvements 
Average (n = 2): 47% 
improvement 
Average  (n = 4): 18% improvement 
1 Mueser et al. (2007)  
2 Mueser et al. (2008)  
3 Nishith et al. (2015) 
4 Mueser et al. (2015) 
5 Steel et al. (2017) 
6 van den Berg et al. (2015) 
7 de Bont et al. (2016)  
aThis table shows the calculation of average percentage improvements in populations of 
individuals with comorbid PTSD and SUD or PTSD and SMI following various treatments, 
including PE alongside SUD treatment as usual, PE integrated with SUD treatment, CPT, SS, 
non-SS CPT, brief CPT, PE alongside SMI treatment as usual, and EMDR. PTSD = 
posttraumatic stress disorder; SUD = substance use disorder; PE = prolonged exposure; TAU = 
treatment as usual; CPT = cognitive processing theory; SS = Seeking Safety; EMDR = eye 
movement desensitization and reprocessing.  
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